

CITATION REPORT

List of articles citing

International consensus report on the investigation and management of primary immune thrombocytopenia

DOI: 10.1182/blood-2009-06-225565
Blood, 2010, 115, 168-86.

Source: <https://exaly.com/paper-pdf/49615825/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1557	Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. 2010 , 32, 1167-1171		27
1556	Recent progress in understanding the pathogenesis of immune thrombocytopenia. 2010 , 17, 590-5		59
1555	Hämatopoetische Wachstumsfaktoren. 2010 , 5, 26-37		
1554	Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. <i>Blood</i> , 2010 , 116, 4783-5	2.2	54
1553	The working group for "Basic science" in ITP at the International Cooperative ITP Study Group (ICIS). 2010 , 89, 3-4		
1552	Mechanisms of platelet recovery in ITP associated with therapy. 2010 , 89 Suppl 1, 31-5		7
1551	Chronic immune thrombocytopenic purpura-who needs medication?. 2010 , 89 Suppl 1, 61-5		14
1550	Editorial 3rd Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting in Basel, Switzerland, September 2009. 2010 , 89 Suppl 1, 1-2		25
1549	Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. 2010 , 89, 1185-95		21
1548	[Hematopoietic growth factors. Possibilities and limitations]. 2010 , 51, 863-71; quiz 872-3		
1547	Short review "Management of Immune Thrombocytopenia in adults. 2010 , 3, 69-72		
1546	Maligne Lymphome der Haut "Update zu Diagnostik und Therapie. 2010 , 5, 4-20		
1545	Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. 2010 , 32, 909-14		13
1544	Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. <i>European Journal of Haematology</i> , 2010 , 85, 502-7	3.8	18
1543	Stability of measurement of the immature platelet fraction. 2010 , 85, 622-4		21
1542	Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. 2010 , 85, 611-3		73
1541	Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location. 2010 , 85, 613-6		49

1540	Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin. 2010 , 85, 624-6	3
1539	Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. 2010 , 85, 627-9	8
1538	Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 2010 , 85, 616-9	16
1537	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. 2010 , 85, 619-22	9
1536	What do healthcare providers ask their patients with immune thrombocytopenia?. 2010 , 85, 629-31	1
1535	Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient. 2010 , 85, 631-3	10
1534	The myths about platelet transfusions in immune-mediated thrombocytopenias. 2010 , 150, 494-5	4
1533	IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia. 2010 , 150, 679-84	19
1532	Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). 2010 , 151, 189-91	17
1531	Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. 2010 , 151, 477-87	52
1530	Maternal autoimmune cytopenias. 45-60	2
1529	Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations. 2010 , 4, 139-45	7
1528	Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. 2010 , 4, 139-45	14
1527	Long-term management of chronic immune thrombocytopenic purpura in adults. 2010 , 3, 305-11	8
1526	Management of immune thrombocytopenia--something old, something new. 2010 , 363, 1959-61	28
1525	Thrombocytopenia in pregnancy. 2010 , 2010, 397-402	76
1524	Beitrag der Durchflusszytometrie zur Diagnose und Differentialdiagnose der Thrombozytopenie / Contribution of flow cytometry to the diagnosis and differential diagnosis of thrombocytopenia. 2010 , 34, 87-92	
1523	Romiplostim or standard of care in patients with immune thrombocytopenia. 2010 , 363, 1889-99	313

1522	Contribution of flow cytometry to the diagnosis and differential diagnosis of thrombocytopenia1. 2010 , 34, -	
1521	Immune thrombocytopenia. 2010 , 2010, 377-84	54
1520	Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam \square 10%) in patients with immune thrombocytopenia. 2010 , 15, 351-9	19
1519	When a child with immune thrombocytopenia experiences life-threatening bleeding. 2010 , 222, 337-9	3
1518	Intracranial hemorrhage in immune thrombocytopenia (ITP): fatal course in spite of maximum therapy. 2010 , 222, 383-5	3
1517	Coincidence of immune thrombocytopenia, intracranial hemorrhage and graft-versus-host disease in an 11-year-old girl. 2010 , 222, 378-82	3
1516	Evaluating bleeding severity in children with newly diagnosed immune thrombocytopenia: a pilot study. 2010 , 222, 374-7	7
1515	Reflexiones sobre el lupus eritematoso sistmico. 2010 , 11, 125-127	
1514	Platelet apoptosis resistance and increased CXCR4 expression in pediatric patients with chronic immune thrombocytopenic purpura. 2010 , 126, 311-8	14
1513	[Evaluation and management of thrombocytopenia]. 2010 , 31 Suppl 3, S324-8	2
1512	[Treatment of adult's immune thrombopenia (ITP)]. 2010 , 31 Suppl 3, S329-32	0
1511	ITP in Patients Infected With Hepatitis C Virus: Practicing With Howard Liebman, MD. 2010 , 7, 58-59	
1510	Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. 2010 , 150, 9-20	57
1509	Rituximab in autoimmune hematologic diseases: not just a matter of B cells. 2010 , 47, 170-9	63
1508	Thrombopoietic agents in immune thrombocytopenia. 2010 , 47, 258-65	13
1507	Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults. 2010 , 12, 881-7	63
1506	Pathogenesis, laboratory, and clinical characteristics of Helicobacter pylori-associated immune thrombocytopenic purpura. 2010 , 52, 131-44	1
1505	Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. 2010 , 26, 1893-903	12

1504	Management of immune thrombocytopenic purpura in children: potential role of novel agents. 2011 , 13, 213-23		10
1503	[What is the prognosis of chronic immune thrombocytopenia?]. 2011 , 74, 317-23		
1502	Acquired Thrombocytopenia. 2011 , 154-173		1
1501	Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region. 2011 , 94, 142-149		9
1500	Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. 2011 , 71, 1333-53		18
1499	Thrombopoietin-receptor agonists for primary immune thrombocytopenia. 2011 , 365, 734-41		86
1498	Acquired disorders affecting megakaryocytes and platelets. 2011 , 523-545		1
1497	Thrombocytopenia in infants and children. 2011 , 32, 135-49; quiz 150-1		6
1496	Eltrombopag for the treatment of immune thrombocytopenia. 2011 , 4, 261-9		13
1495	Rituximab therapy for autoimmune haematological diseases. 2011 , 22, 220-9		52
1494	Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary?. 2011 , 170, e225-32		33
1493	Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. 2011 , 55, 229-32		35
1492	Current treatment options for primary immune thrombocytopenia. 2011 , 4, 107-18		20
1491	Eight-year follow-up of patients with immune thrombocytopenic purpura related to H. pylori infection. 2011 , 22, 61-4		24
1490	The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i> , 2011 , 117, 4190-207	2.2	1322
1489	[Protocol for the study and treatment of immune thrombocytopenic purpura (ITP). ITP-2010]. 2011 , 74, 414.e1-8		5
1488	Sustaining platelet counts in chronic ITP. 2011 , 377, 358-60		3
1487	Romiplostim: Idiopathic Thrombocytopenic Purpura (Children/Adolescents). 2011 , 46, 755-757		

1486	Rituximab: Primary Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura). 2011 , 46, 251-253		
1485	Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. 2011 , 26, 449-54		22
1484	Immune thrombocytopenia: no longer 'idiopathic'. 2011 , 78, 358-73		44
1483	The wandering spleen: an unusual case of thrombocytopenia. <i>Journal of Blood Medicine</i> , 2011 , 2, 161-3	2.3	6
1482	Long-term outcome of isolated thrombocytopenia accompanied by hypocellular marrow. 2011 , 46, 128-34		1
1481	Advances in ITP--therapy and quality of life--a patient survey. <i>PLoS ONE</i> , 2011 , 6, e27350	3.7	13
1480	Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia. 2011 , 33, 265-9		16
1479	A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?. 2011 , 23, 455-60		15
1478	Eltrombopag for the treatment of chronic immune thrombocytopenia. 2011 , 1, 295-303		1
1477	Immune (idiopathic) thrombocytopenic purpura in a 21-year-old student. 2011 , 24, E1-E3		
1476	Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. <i>Blood</i> , 2011 , 117, 6673-80	2.2	197
1475	Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. <i>Blood</i> , 2011 , 117, 3514-20	2.2	82
1474	A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. <i>Blood</i> , 2011 , 118, 28-36	2.2	168
1473	Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. <i>Blood</i> , 2011 , 117, 5723-32	2.2	114
1472	Oxidative stress may cause ITP. <i>Blood</i> , 2011 , 117, 4405-6	2.2	4
1471	Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. <i>Blood</i> , 2011 , 118, 4338-45	2.2	91
1470	Differential roles of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia. 2011 , 112, 1034-40		15
1469	[Pharmacological and clinical profile of romiplostim (Romiplate(®) 250 µg for s.c. injection)]. 2011 , 138, 34-9		

1468	Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia. 2011 , 43, 520-2		6
1467	Evaluation of Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura. 2011 , 53, 701-705		0
1466	Transfusion tomorrow: Royal College of Pathologists, November 2010. 2011 , 21, 224-30		2
1465	Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. 2011 , 152, 52-60		38
1464	ITP: a historical perspective. 2011 , 153, 437-50		52
1463	Decreased expression of interleukin-27 in immune thrombocytopenia. 2011 , 153, 259-67		18
1462	Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. 2011 , 154, 14-22		62
1461	The experience of Flebogammadif [®] in primary immune thrombocytopenia. 2011 , 164 Suppl 2, 12-5		6
1460	The development of romiplostim for patients with immune thrombocytopenia. 2011 , 1222, 55-63		35
1459	Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2011 , 86, 256-9	3.8	1
1458	Determination of platelet-bound glycoprotein-specific autoantibodies by flow cytometric immunobead assay in primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2011 , 86, 339-46	3.8	6
1457	Fatigue in adult patients with primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2011 , 86, 420-9	3.8	50
1456	Predictive value of response to steroid therapy on response to splenectomy in children with immune thrombocytopenic purpura. 2011 , 150, 643-8		5
1455	Increased expressions of DNA methyltransferases contribute to CD70 promoter hypomethylation and over expression of CD70 in ITP. 2011 , 48, 1525-31		9
1454	Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. 2011 , 33, 1560-76		20
1453	The CD47 pathway is deregulated in human immune thrombocytopenia. 2011 , 39, 486-94		16
1452	Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia. 2011 , 141, 121-3		27
1451	Effects of CD70 and CD11a in immune thrombocytopenia patients. 2011 , 31, 632-42		6

1450	Maternale Thrombozytopenie und Thrombozytopathie. 2011 , 44, 527-532	1
1449	Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. 2011 , 94, 71-80	77
1448	Skewed T-cell subsets and enhanced macrophages phagocytosis in the spleen of patients with immune thrombocytopenia failing glucocorticoids. 2011 , 94, 248-254	12
1447	Rituximab. 2011 , 48, 627-32	18
1446	Platelet disorders in children: A diagnostic approach. 2011 , 56, 975-83	46
1445	Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. 2011 , 86, 278-91	15
1444	ASH 2010 meeting report—top 10 clinically oriented abstracts in coagulation medicine and platelet disorders. 2011 , 86, 443-445	
1443	Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. 2011 , 86, 785-7	8
1442	Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. 2011 , 86, 790-2	8
1441	Sideroblastic anemia, iron overload, and ALAS2 R452S in African-American males: phenotype and genotype features of five unrelated patients. 2011 , 86, 787-9	2
1440	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. 2011 , 86, 796-800	34
1439	An evaluation of concurrent G6PD (A-) deficiency and sickle cell trait in Malian populations of children with severe or uncomplicated <i>P. falciparum</i> malaria. 2011 , 86, 795-6	9
1438	Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia. 2011 , 86, 792-4	2
1437	Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients. 2011 , 86, 800-3	
1436	Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. 2011 , 86, 804-6	23
1435	Changing patterns of splenectomy in transfusion-dependent thalassemia patients. 2011 , 86, 808-10	23
1434	Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. 2011 , 86, 806-8	32
1433	Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. 2011 , 86, 980-4	40

1432	Non-Hodgkin lymphoma and autoimmunity: does gender matter?. 2011 , 129, 460-6	30
1431	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. 2011 , 35, 863-7	34
1430	Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. 2011 , 96, 632-4	25
1429	Childhood immune thrombocytopenia: a changing therapeutic landscape. 2011 , 37, 745-55	21
1428	Guidelines for immune thrombocytopenia. 2011 , 364, 580-1; author reply 581	7
1427	The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. 2011 , 96, 1560-4	81
1426	Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. 2011 , 22, 153-6	21
1425	Thrombocytopenia and disorders of platelet function in pregnancy. 2011 , 37, 640-52	27
1424	Immunomodulatory effects of intravenous immunoglobulins (IVIg) in HIV-1 disease: a systematic review. 2011 , 30, 44-66	5
1423	Immune thrombocytopenia and pregnancy. 2011 , 4, 140-6	7
1422	Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. 2011 , 3, e20	11
1421	Idiopathic thrombocytopenic purpura coexisting with polycythemia vera. 2011 , 5, 187-8	1
1420	What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists. 2011 , 20, 301-2	
1419	Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. 2011 , 96, 1831-7	82
1418	Massive pulmonary embolism and cardio-pulmonary resuscitation leading to disseminated intravascular coagulation. 2011 , 5, 188-9	
1417	Bleeding During Pregnancy. 2011 ,	1
1416	Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. 2011 , 16, 274-7	17
1415	What to do when you suspect an inherited platelet disorder. 2011 , 2011, 377-83	26

- 1414 Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. **2011**, 2011, 384-90 32
- 1413 DIAGNOSIS AND MANAGEMENT OF THROMBOCYTOPENIA IN PREGNANCY. **2011**, 22, 144-167 2
- 1412 Dapsone (Adults): Idiopathic Thrombocytopenic Purpura (Primary Immune Thrombocytopenia). **2011**, 46, 415-426
- 1411 Mycophenolate Mofetil: Idiopathic Thrombocytopenic Purpura (Primary Immune Thrombocytopenia). **2011**, 46, 569-571
- 1410 CD72 gene expression in immune thrombocytopenia. **2012**, 23, 638-44 6
- 1409 Autoimmune cytopenias in common variable immunodeficiency. **2012**, 3, 189 35
- 1408 Solar radiation and vitamin D: mitigating environmental factors in autoimmune disease. **2012**, 2012, 619381 31
- 1407 Yenidođın ve sf.öcukluđında kolestaz. **2012**, 47, 1-7
- 1406 Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia. **2012**, 4, e2012003 7
- 1405 Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. **2012**, 18, 287-92 38
- 1404 Thrombotic microangiopathy and Purtscher-like retinopathy as a rare presentation of juvenile dermatomyositis. **2012**, 129, e821-4 15
- 1403 Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia. **2012**, 46, e31 3
- 1402 The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. **2012**, 19, 357-62 50
- 1401 Perinatal outcome for pregnancies complicated with thrombocytopenia. **2012**, 25, 1622-6 7
- 1400 Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review. **2012**, 38, 463-8 25
- 1399 [Percutaneous coronary intervention in a patient with acute myeloid leukemia]. **2012**, 137, 1092-5 5
- 1398 Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. **2012**, 28, 249-58 26
- 1397 Newly diagnosed immune thrombozytopenia--German guideline concerning initial diagnosis and therapy. **2012**, 224, 207-10 1

1396	[Treatment outcome of immune thrombocytopenia]. 2012 , 153, 1613-21		
1395	Romiplostim for the treatment of primary immune thrombocytopenia. 2012 , 5, 133-44		2
1394	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. 2012 , 47, 770-90		194
1393	A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. 2012 , 28, 789-96		7
1392	Use of romiplostim for primary immune thrombocytopenia in children. 2012 , 29, 197-205		23
1391	Changing trends in the UK management of childhood ITP. 2012 , 97, 8-11		27
1390	Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. 2012 , 189, 5105-11		64
1389	Lessons learned from a case of abdominal aortic aneurysm accompanied by unstable coagulopathy. 2012 , 2012, 265860		3
1388	Myelofibrosis associated with romiplostim treatment in a patient with immune thrombocytopenia. 2012 , 2012, 318597		2
1387	Immunological HCV-associated thrombocytopenia: short review. 2012 , 2012, 378653		9
1386	Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. <i>Therapeutic Advances in Hematology</i> , 2012 , 3, 155-64	5-7	34
1385	A retrospective observational single-centre study on the burden of immune thrombocytopenia (ITP). 2012 , 35, 342-8		2
1384	The clinical significance of circulating B cells secreting anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein IIb/IIIa in patients with primary immune thrombocytopenia. 2012 , 17, 283-90		18
1383	Clinical features, prognostic factors, and their relationship with antiplatelet antibodies in children with immune thrombocytopenia. 2012 , 34, 6-12		12
1382	Thrombophies. 2012 , 7, 1-9		
1381	Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 331-4	1	6
1380	Severe steroid-resistant thrombocytopenia secondary to cytomegalovirus infection in an immunocompetent adult. 2012 , 51, 1747-50		6
1379	Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP). 2012 , 17 Suppl 1, S25-7		4

1378	Thrombopoietin: too much or too little. 2012 , 17 Suppl 1, S166-8		1
1377	Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. <i>Blood</i> , 2012 , 120, 3670-6	2.2	39
1376	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. <i>Blood</i> , 2012 , 119, 1356-62	2.2	92
1375	Abnormalities in IgA and IgM are associated with treatment-resistant ITP. <i>Blood</i> , 2012 , 119, 5016-20	2.2	7
1374	Diagnosis and Treatment of Idiopathic Thrombocytopenic Purpura. 2012 , 17, 25-28		1
1373	Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study. 2012 , 51, 859-63		14
1372	Contemporary management of primary immune thrombocytopenia in adults. 2012 , 10, 1988-98		46
1371	Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>European Journal of Haematology</i> , 2012 , 89, 361-4	3.8	14
1370	Risk and prognosis of adult primary immune thrombocytopenia. 2012 , 5, 219-28		8
1369	Immune thrombocytopenia in adults: an update. 2012 , 79, 641-50		29
1368	Idiopathic thrombocytopenic purpura in childhood: twenty years of experience in a single center. 2012 , 54, 524-7		11
1367	[Thrombocytopenia and pregnancy]. 2012 , 33, 446-52		8
1366	La splhnectomie dans le purpura thrombophique immunologique de l'enfant : Pour qui ? Quand ? Comment ?. 2012 , 19, H170-H171		
1365	Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients. 2012 , 15, 112-24		7
1364	How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. <i>Blood</i> , 2012 , 120, 960-9	2.2	165
1363	Platelets in inflammation and immune modulations: functions beyond hemostasis. 2012 , 60, 443-51		23
1362	An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. 2012 , 47, 1537-41		7
1361	Romiplostim overcomes refractory secondary immune thrombocytopenia in a patient affected by serous ovarian carcinoma. 2012 , 1, 239-242		

1360	The use of monoclonal antibodies in immune-mediated hematologic disorders. 2012 , 96, 583-619, xi		4
1359	[Chronic idiopathic thrombocytopenia outcome during pregnancy (62 cases)]. 2012 , 33, 426-32		4
1358	Thrombosis in patients with primary chronic immune thrombocytopenia. 2012 , 130 Suppl 1, S74-5		22
1357	Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. 2012 , 28, 79-87		58
1356	[Management of immune thrombocytopenia in France before the era of thrombopoietin receptor agonists]. 2012 , 33, 305-10		3
1355	Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura. 2012 , 505, 53-6		17
1354	Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. <i>Blood</i> , 2012 , 120, 5021-31	2.2	41
1353	Romiplostim: a review of its use in immune thrombocytopenia. 2012 , 72, 415-35		12
1352	Alteraciones de la hemostasia primaria. Púrpuras y alteraciones de las plaquetas. 2012 , 11, 1337-1344		1
1351	[A sus-clavicular adenopathy in patient with PIP breast implants]. 2012 , 41, 1153-5		
1350	Deep thrombocytopenia due to dengue fever in a patient splenectomized for immune thrombocytopenia. 2012 , 41, 1151-3		2
1349	[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]. 2012 , 138, 261.e1-261.e17		13
1348	Trombocitopenias. 2012 , 16, 1-9		
1347	Trombocitopenie. 2012 , 14, 1-9		
1346	Thrombophilie et grossesse. 2012 , 16, 323-334		
1345	Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. 2012 , 96, 594-9		6
1344	Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia. 2012 , 91, 1497-8		5
1343	Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. 2012 , 21, 386-401		51

1342	The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. 2012 , 15, 956-76	9
1341	Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. 2012 , 23, 423-9	23
1340	Disorders of Thrombosis and Hemostasis in Pregnancy. 2012 ,	8
1339	Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia. 2012 , 32, 1233-42	15
1338	Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions. 2012 , 49, 811-8	11
1337	Rituximab for children with immune thrombocytopenia: a systematic review. <i>PLoS ONE</i> , 2012 , 7, e36698	3.7 59
1336	The ratio of Treg/Th17 cells correlates with the disease activity of primary immune thrombocytopenia. <i>PLoS ONE</i> , 2012 , 7, e50909	3.7 70
1335	Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. 2012 , 107, 937-50	32
1334	Thrombocytopenia. 2012 , 1124-1131	1
1333	Safety and Efficacy of Romiplostim in Patients with Severe, Chronic Idiopathic Thrombocytopenic Purpura. 2012 , 4, CMT.S7440	
1332	How to approach thrombocytopenia. 2012 , 2012, 191-197	118
1331	Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. 2012 , 4, e10	2
1330	Severe immune thrombocytopenic purpura treated with plasma exchange. 2012 , 10, 85-7	5
1329	Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. 2012 , 58, 216-20	12
1328	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. 2012 , 58, 221-5	26
1327	Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. 2012 , 156, 508-15	36
1326	Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. 2012 , 87, 558-61	52
1325	The platelet count in EDTA-anticoagulated blood from patients with thrombocytopenia may be underestimated when measured in routine laboratories. 2012 , 87, 727-8	7

1324	Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. 2012, 87, 843-7		11
1323	Prevalence of primary immune thrombocytopenia in Oklahoma. 2012, 87, 848-52		46
1322	Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. 2012, 87, 936-7		12
1321	Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. 2012, 87, 984-7		13
1320	Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective. 2012, 87, 946-7		6
1319	Bmi-1 regulates autoreactive CD4+ T cell survival in immune thrombocytopenia patients. 2012, 32, 505-13		17
1318	Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. 2012, 32, 523-9		41
1317	An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). 2012, 95, 652-9		30
1316	Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. 2012, 96, 26-33		18
1315	Severe Thrombocytopenia in an Immune Thrombocytopenic Parturient Non-responder to Medical Line of Treatment: Anaesthetic Management for Splenectomy Combined with Caesarean Section. 2012, 28, 54-7		2
1314	[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (GHO)]. 2012, 124, 111-23		4
1313	Therapeutic options for immune-mediated thrombocytopenia. 2012, 22, 59-72		12
1312	Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 729-32	2.2	15
1311	RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). 2012, 52, 1126-36; quiz 1125		42
1310	A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. 2012, 10, 799-806		64
1309	Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort. 2012, 101, 761-6		36
1308	Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). <i>European Journal of Haematology</i> , 2012, 88, 167-74	3.8	78
1307	Thrombocytopenia and platelet activity in dogs experimentally infected with <i>Rangelia vitalii</i> . 2012, 185, 131-7		14

1306	Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment. 2012 , 157, 256-8	8
1305	Management of autoimmune diseases after haematopoietic stem cell transplantation. 2012 , 157, 281-90	65
1304	Diagnosis and management of maternal thrombocytopenia in pregnancy. 2012 , 158, 3-15	50
1303	Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?. 2012 , 158, 16-29	75
1302	Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. 2012 , 158, 386-98	57
1301	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. 2012 , 158, 528-38	28
1300	Treatment of primary autoimmune thrombocytopenia (AITP) [1]. 2012 , 102, 261-8	
1299	Rapid update on childhood immune thrombocytopenic purpura. 2012 , 48, 378-9	1
1298	Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. 2012 , 42, e12-4	8
1297	Presentation and outcome of idiopathic thrombocytopenic purpura in a single Australian centre. 2012 , 42, 841-5	8
1296	Reliable predictors of neonatal immune thrombocytopenia in pregnant women with idiopathic thrombocytopenic purpura. 2012 , 87, 15-21	43
1295	Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIb/IIIa versus GPIIb/IIIa antibodies. 2012 , 87, 206-8	67
1294	Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. 2012 , 87, 211-3	3
1293	The potential role of pre-transplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network. 2012 , 87, 213-7	13
1292	TP53 mutations and polymorphisms in primary myelofibrosis. 2012 , 87, 204-6	10
1291	Practical approach for characterization of glucose 6-phosphate dehydrogenase (G6PD) deficiency in countries with population ethnically heterogeneous: description of seven new G6PD mutants. 2012 , 87, 208-10	3
1290	Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. 2012 , 87, 217-9	27
1289	Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant. 2012 , 87, 219-21	20

1288	Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. 2012 , 87, 221-3	19
1287	Complications of implantable venous access devices in patients with sickle cell disease. 2012 , 87, 224-6	16
1286	Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma. 2012 , 87, 226-8	7
1285	Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer. 2012 , 87, 230-2	1
1284	The diagnostic value of biopsy of small peripheral lymph nodes in patients with suspected lymphoma. 2012 , 87, 228-30	2
1283	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 2012 , 87, 203-4	22
1282	Sequence of treatments for adults with primary immune thrombocytopenia. 2012 , 87 Suppl 1, S12-5	14
1281	Hämatologische Erkrankungen in der Schwangerschaft. 2012 , 45, 95-102	2
1280	The bleeding child. Part I: primary hemostatic disorders. 2012 , 171, 1-10	19
1279	Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions. 2013 , 104, 55-66	11
1278	Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia. 2013 , 33, 938-46	7
1277	The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopenia. 2013 , 6, 28	11
1276	Use of diffusion-ordered NMR spectroscopy and HPLC-UV-SPE-NMR to identify undeclared synthetic drugs in medicines illegally sold as phytotherapies. 2013 , 51, 541-8	9
1275	Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab. 2013 , 13, 4	21
1274	Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. 2013 , 98, 323-30	20
1273	Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia. 2013 , 97, 610-6	16
1272	Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. 2013 , 162, 693-701	21
1271	Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. 2013 , 28, 145-284	455

1270	Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases. 2013 , 92, 661-7	17
1269	Histiocytic sarcoma simulating immune thrombocytopenic purpura. 2013 , 92, 555-6	
1268	Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. 2013 , 92, 67-78	31
1267	Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. 2013 , 92, 79-87	22
1266	Pathophysiology and management of primary immune thrombocytopenia. 2013 , 98, 24-33	54
1265	Hematologic complications of pregnancy. 2013 , 50, 222-31	90
1264	Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland. 2013 , 11, 457-69	14
1263	Case records of the Massachusetts General Hospital. Case 27-2013. A 6.5-month-old boy with fever, rash, and cytopenias. 2013 , 369, 853-63	4
1262	SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. 2013 , 9, 281-96	26
1261	Combined plasma exchange and platelet transfusion in immune-mediated thrombocytopenic emergencies. 2013 , 49, 661-4	8
1260	Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children. 2013 , 19, 666-9	15
1259	Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. <i>European Journal of Haematology</i> , 2013 , 91, 546-51	3.8 37
1258	Thrombopoietin receptor agonists in primary immune thrombocytopenia. 2013 , 50 Suppl 1, S18-21	29
1257	Contemporary treatment of immune thrombocytopenia. 2013 , 6, 697-712	4
1256	Quality of life in immune thrombocytopenia following treatment. 2013 , 98, 895-7	14
1255	Ràanimation et cytophies auto-immunes. Diagnostic et modalitš de prise en charge. 2013 , 22, 490-500	
1254	Helicobacter pylori and autoimmune diseases. 2013 , 67, 347-9	8
1253	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. 2013 , 9, 281-296	1

1252	Immune thrombocytopenia. 2013 , 27, 495-520		102
1251	Evaluation of health related quality of life in children with immune thrombocytopenia with the PedsQL 4.0 Generic Core Scales: a study on behalf of the Pays de Loire pediatric hematology network. 2013 , 11, 193		10
1250	Cellular immune dysfunction in immune thrombocytopenia (ITP). 2013 , 163, 10-23		121
1249	Immune thrombocytopenia -- what are the new treatment options?. 2013 , 13, 1173-85		13
1248	Advances in immunopathogenesis of adult immune thrombocytopenia. 2013 , 7, 418-24		13
1247	Bone mass and biochemical markers of bone turnover in children and adolescents with chronic immune thrombocytopenia: relation to corticosteroid therapy and vitamin D receptor gene polymorphisms. 2013 , 24, 282-7		7
1246	Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. 2013 , 11, 1946-53		18
1245	Adverse postoperative outcomes in surgical patients with immune thrombocytopenia (Br J Surg 2013; 100: 684-692). 2013 , 100, 693-693		
1244	Análisis del coste del tratamiento farmacológico de la trombocitopenia inmune primaria mediante agonistas del receptor de la trombopoyetina en España. 2013 , 10, 99-106		
1243	Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities. 2013 , 24, 242-3		
1242	Investigating an incidental finding of thrombocytopenia. 2013 , 346, f11		4
1241	Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. 2013 , 50, 212-7		40
1240	How I treat thrombocytopenia in pregnancy. <i>Blood</i> , 2013 , 121, 38-47	2.2	164
1239	Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). 2013 , 160, 538-46		45
1238	Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura. 2013 , 35, 228-33		12
1237	Update on the Intercontinental Cooperative ITP Study Group (ICIS) and on the Pediatric and Adult Registry on Chronic ITP (PARC ITP). 2013 , 60 Suppl 1, S15-8		11
1236	Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. 2013 , 60 Suppl 1, S12-4		8
1235	Bleeding severity as an important outcome in childhood immune thrombocytopenia. 2013 , 60 Suppl 1, S8-11		4

1234	Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. 2013 , 28, 335-41	43
1233	Cell death in immune thrombocytopenia: novel insights and perspectives. 2013 , 50 Suppl 1, S109-15	10
1232	Immune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligand. 2013 , 50 Suppl 1, S89-99	13
1231	Immune thrombocytopenia patients requiring anticoagulation--maneuvering between Scylla and Charybdis. 2013 , 50 Suppl 1, S83-8	24
1230	Actualit� du purpura thrombophique immunologique. 2013 , 2013, 14-18	0
1229	B-cell depletion in immune thrombocytopenia. 2013 , 50 Suppl 1, S75-82	13
1228	Menorrhagia and rash in a female adolescent. 2013 , 27, 209-14	
1227	Thrombocytopenia. 2013 , 41, 225-227	2
1226	Maopytkowolawskazania do zastosowania cytokin p�tkotw�rczych. 2013 , 44, 130-134	
1225	Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia. 2013 , 50 Suppl 1, S31-8	4
1224	Chronic immune thrombocytopenia in children: who needs splenectomy?. 2013 , 50 Suppl 1, S58-62	10
1223	Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. 2013 , 160, 228-36	11
1222	The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). 2013 , 160, 237-43	16
1221	Severe cutaneous toxicity related to Eltrombopag. 2013 , 160, 412-4	7
1220	Immune Thrombocytopenia (ITP). 2013 , 819-833	4
1219	Thrombocytopenia in Pregnancy. 2013 , 909-928	
1218	My patient is thrombocytopenic! Is (s)he? Why? And what shall I do? A practical approach to thrombocytopenia. <i>Hamostaseologie</i> , 2013 , 33, 83-94	1.9 10
1217	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. 2013 , 161, 411-23	180

1216	High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2013 , 90, 494-500	3.8	36
1215	A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production. 2013 , 24, 98-106		19
1214	To treat or not to treat--from guidelines to individualized patient management. 2013 , 50 Suppl 1, S12-7		2
1213	The role of <i>Helicobacter pylori</i> infection in hematological disorders. 2013 , 24, 685-90		35
1212	Perioperative Management of Patients with Rheumatic Disease. 2013 ,		2
1211	Autoimmunity and novel therapies in immune-mediated thrombocytopenia. 2013 , 50 Suppl 1, S100-8		14
1210	Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. 2013 , 161, 778-93		63
1209	Romiplostim as early treatment for refractory primary immune thrombocytopenia. 2013 , 98, 520-4		13
1208	Maternal thrombocytopenia in pregnancy: diagnosis and management. 2013 , 33, 327-41		10
1207	Commentary on session: Immune thrombocytopenia nomenclature, guidelines, and natural history. 2013 , 50 Suppl 1, S10-1		2
1206	Immune thrombocytopenia nomenclature, consensus reports, and guidelines: what are the consequences for daily practice and clinical research?. 2013 , 50 Suppl 1, S50-4		26
1205	Occult hemorrhage in immune thrombocytopenia. 2013 , 50 Suppl 1, S26-30		3
1204	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. 2013 , 103-116		6
1203	Haemolysis secondary to intravenous immunoglobulins for ITP. 2013 , 18, 178-80		2
1202	Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Quebec, Canada. 2013 , 16, 318-26		7
1201	Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders. 2013 , 125, 65-72		20
1200	Treatment guidelines & algorithm. 2013 , 30-45		
1199	Platelet Disorders in Children. 2013 , 42-58		

1198	Severe Case of Autoimmune Thrombocytopenia First Diagnosed in Pregnancy. 2013 , 73, 1252-1255		
1197	Cardiac surgery in a patient with immunological thrombocytopenic purpura: complications and precautions. 2013 , 16, 147-50		7
1196	The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. 2013 , 5, e2013027		3
1195	Hematological Problems in Pediatric Intensive Care. 2013 , 42-66		
1194	Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2013 , 24, 732-5	1	1
1193	Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2013 , 24, 284-96	1	9
1192	Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children's hospitals. 2013 , 131, 880-5		24
1191	Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities. 2013 , 39, 794-802		21
1190	Thrombophies immunologiques. 2013 , 261-277		
1189	Therapeutic Apheresis. 2013 , 546-562		
1188	Platelet antibodies, activated platelets and serum leptin in childhood immune thrombocytopenic purpura. 2013 , 130, 312-8		5
1187	FcR11a and FcR11a polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome. <i>Blood Coagulation and Fibrinolysis</i> , 2013 , 24, 35-9	1	13
1186	Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. 2013 , 162, 112-9		66
1185	Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine. 2013 , 52, 1239-42		8
1184	Idiopathic thrombocytopenia with iron deficiency anemia. 2013 , 6, 1-5		0
1183	Diagnosis, treatment, and management of immune thrombocytopenia. 2013 , 17, 664-6		2
1182	Some viral microRNAs were up-regulated in megakaryocytes incubated with immune thrombocytopenia plasma. <i>European Journal of Haematology</i> , 2013 , 90, 220-7	3.8	7
1181	Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. 2013 , 88, 1041-4		45

1180	Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. 2013 , 88, 858-61		22
1179	Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim. <i>European Journal of Haematology</i> , 2013 , 91, 376-7	3.8	11
1178	Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. <i>European Journal of Haematology</i> , 2013 , 90, 438-9	3.8	7
1177	Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. <i>European Journal of Haematology</i> , 2013 , 91, 236-41	3.8	44
1176	Hematocrit and flow rate regulate the adhesion of platelets to von Willebrand factor. 2013 , 7, 64113		30
1175	Chest pain, dyspnea, petechiae, and melena in a 58-year-old woman - what is it?. 2013 , 24, 415-8		
1174	Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. <i>European Journal of Haematology</i> , 2013 , 91, 423-36	3.8	67
1173	Adverse postoperative outcomes in surgical patients with immune thrombocytopenia. 2013 , 100, 684-92; discussion 693		12
1172	Primary Immune Thrombocytopenia. 2013 , 117-131		
1171	Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?. 2013 , 2013, 283-5		10
1170	Current management of immune thrombocytopenia. 2013 , 2013, 276-82		62
1169	Paediatric and Adolescent Immune Thrombocytopenia: Prevention of Bleeding versus Burden of Treatment. 2013 , 16-29		
1168	Anti-D immunoglobulin therapy for pediatric ITP: before and after the FDA's black box warning. 2013 , 60, E149-51		11
1167	Current & Emerging Treatments for Immune Thrombocytopenia. 2013 ,		
1166	Platelet transfusion. 2013 , 102-109		
1165	Ulcerative colitis accompanied by idiopathic thrombocytopenic purpura and Helicobacter pylori infection. 2013 , 52, 547-9		4
1164	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. <i>Blood</i> , 2013 , 121, 537-45	2.2	236
1163	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. <i>Blood</i> , 2013 , 121, 2596-606	2.2	126

1162	Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. <i>Blood</i> , 2013 , 121, 1976-81	2.2	109
1161	Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. <i>Blood</i> , 2013 , 121, 4938-47	2.2	86
1160	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). <i>Blood</i> , 2013 , 121, 4457-62	2.2	65
1159	Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. <i>Blood</i> , 2013 , 122, 2477-86	2.2	30
1158	Better late than never?. <i>Blood</i> , 2013 , 122, 1844-5	2.2	2
1157	Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ib and Fc RIIa in immune thrombocytopenia. 2013 , 98, e70-2		15
1156	Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant. 2013 , 35, e174-7		2
1155	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. 2013 , 98, 875-80		76
1154	Symptoms and diagnosis. 2013 , 18-29		
1153	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. 2013 , 98, 881-7		58
1152	[Case report; a thromboembolic event in a patient with antiphospholipid antibody associated thrombocytopenia during eltrombopag therapy]. 2013 , 102, 1461-3		2
1151	Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia. 2013 , 109, 263-71		45
1150	Glycosylation of autoantibodies: insights into the mechanisms of immune thrombocytopenia. 2013 , 110, 1259-66		16
1149	Acquired Neonatal Thrombocytopenia. 2013 , 615-619		
1148	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. 2013 , 5, 17-30		10
1147	Differential expression of T-cell genes in blood and bone marrow between ITP patients and controls. 2013 , 109, 112-7		5
1146	Guidelines on the diagnosis of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012. 2013 , 35, 358-65		5
1145	Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia. 2013 , 48, 297-8		1

1144	Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. 2013 , 40, 319-25	43
1143	Dexamethasone: idiopathic thrombocytopenic purpura in children and adolescents. 2013 , 48, 108-10	1
1142	Autoimmune cytopenias in chronic lymphocytic leukemia. 2013 , 2013, 730131	9
1141	Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. 2013 , 13, 50-8	18
1140	Cardiovascular disease. 247-266	
1139	Autoimmune disease in pregnancy. 391-402	0
1138	Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths. 2013 , 5, e2013068	9
1137	Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection. 2013 , 53, 151-5	9
1136	PharmaForum. 2013 , 36, 689-693	
1135	A Case of Immune Thrombocytopenic Purpura Accompanying Ulcerative Colitis. 2014 , 64, 234	
1134	The Platelet as a Target for Damage. 2014 , 3115-3138	0
1133	Safety and efficacy of Gammaplex [®] in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075). <i>PLoS ONE</i> , 2014 , 9, e96600	3-7 13
1132	Modified titanium implant as a gateway to the human body: the implant mediated drug delivery system. 2014 , 2014, 801358	18
1131	An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. 2014 , 2014, 341342	13
1130	Sustained Responses following Treatment with Romiplostim in Immune Thrombocytopenia: A Single-Centre Experience. 2014 , 02,	1
1129	Spontaneous Periocular Ecchymosis in Children: Differential Diagnosis and Current Trends in Evaluation and Management. 2014 , 05,	
1128	. 2014 ,	2
1127	. 2014 ,	2

1126	Perioperative management of a case of frontal glioma with idiopathic thrombocytopenic purpura. 2014, 01, 211-213		
1125	Concealed vascular injury during coiling of intracranial aneurysm leading to severe resistant hypotension and poor outcome: The lesson learnt. 2014, 01, 213-215		1
1124	Value of vanin-1 assessment in adult patients with primary immune thrombocytopenia. 2014, 25, 86-92		4
1123	Acute and Chronic Immune Thrombocytopenia: Biology, Diagnosis, and Management. 2014, 137-150		
1122	Immune Thrombocytopenia. 2014,		
1121	Progressive bruising in an otherwise healthy child: immune thrombocytopenia purpura. 2014, 16, 158-9		
1120	Feasible concomitant treatment with eltrombopag and oral anticoagulation in a patient with chronic immune thrombocytopenia and severe cardiac comorbidities. 2014, 25, 309-10		1
1119	Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia. 2014, 7, 149-154		9
1118	ITP-QoL questionnaire for children with immune thrombocytopenia: Italian version validation's. 2014, 31, 534-47		13
1117	Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic Purpura. 2014, 31, 32-9		12
1116	Immunthrombozytopenie: Pathophysiologie, Diagnostik, Therapie. 2014, 4, 88-102		
1115	The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 376-82	2.2	5
1114	Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration. 2014, 44, 519-21		2
1113	A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?. 2014, 167, 110-20		11
1112	Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. 2014, 164, 266-71		29
1111	Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. 2014, 12, 497-504		69
1110	Rituximab in previously treated primary immune thrombocytopenia patients: evaluation of short- and long-term efficacy and safety. 2014, 132, 24-9		3
1109	Bleeding management in pediatric patients. 2014, 40,		78

1108	Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia. 2014 , 19, 477-82	7
1107	Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists. 2014 , 347, 190-4	12
1106	Lymphocyte subsets in primary immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2014 , 25, 816-9	1 3
1105	Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia. 2014 , 168, e142214	13
1104	Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag. 2014 , 25, 55-61	7
1103	Hämatologische Labordiagnostik bei Thrombozyten. 2014 , 38,	
1102	Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. 2014 , 20, 714-23	49
1101	Management of thrombocytopenia. 2014 , 6, 45	53
1100	Do we need 'routine' blood counts?. 2014 , 75, 644-6	2
1099	CD4+ CD25+High Foxp3+ regulatory T cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut Children Hospital. 2014 , 20, 61-7	15
1098	[Comparison of international guidelines for primary autoimmune thrombocytopenia]. 2014 , 143, 408-19	2
1097	Benefits and risks of splenectomy. 2014 , 12, 113-9	86
1096	Is B-cell depletion still a good strategy for treating immune thrombocytopenia?. 2014 , 43, e79-85	11
1095	Rare cause of bleeding in a young footballer. 2014 , 5, 91-93	
1094	Study of T-cell immunoglobulin- and mucin-domain-containing molecule 3 polymorphisms in Egyptian childhood immune thrombocytopenic purpura. 2014 , 23, 933-939	2
1093	Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding. 2014 , 93, 309-15	19
1092	Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group. 2014 , 37, 279-86	17
1091	Diagnosis and classification of immune-mediated thrombocytopenia. 2014 , 13, 577-83	46

1090	The Coagulation Consult. 2014 ,	1
1089	Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia. 2014 , 99, 597-602	8
1088	The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 2014 , 7, 59	6
1087	Clinical practice: immune thrombocytopenia in paediatrics. 2014 , 173, 163-72	34
1086	BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation. 2014 , 133, 73-9	17
1085	Immune Thrombocytopenia. 2014 , 663-675	
1084	Immune thrombocytopenic purpura: major progress in knowledge of the pathophysiology and the therapeutic strategy, but still a lot of issues. 2014 , 43, e47-8	9
1083	Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods. 2014 , 29, 53-60	23
1082	Drugs Targeting B-Cells in Autoimmune Diseases. 2014 ,	3
1081	The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. 2014 , 47, 519-29	20
1080	Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. 2014 , 89, 41-6	33
1079	The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study. 2014 , 89, 1047-50	16
1078	Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women. 2014 , 166, 929-35	52
1077	Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia. 2014 , 44, 697-9	7
1076	Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP): a retrospective cohort study on longtime response predicting factors based on consensus criteria. 2014 , 12, 1428-33	26
1075	Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. 2014 , 89, 194-8	24
1074	[Antenatal management for patients with increased risk of post-partum hemorrhage (excluding abnormal placentation)]. 2014 , 43, 951-65	3
1073	Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura. 2014 , 31, 555-62	5

1072	Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines. 2014 , 23, 554-67	47
1071	Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. 2014 , 13, 1055-63	46
1070	Hémorragie intracrânienne compliquant un purpura thrombophrigue immunologique aigu de lâenfant: une tude rtrospective nationale. 2014 , 2, 113-125	1
1069	Approach to Thrombocytopenia. 2014 , 219-223	
1068	Decreased IL-35 levels in patients with immune thrombocytopenia. 2014 , 75, 909-13	19
1067	Quercetin, but not its metabolite quercetin-3-glucuronide, exerts prophylactic immunostimulatory activity and therapeutic antiinflammatory effects on lipopolysaccharide-treated mouse peritoneal macrophages ex vivo. 2014 , 62, 2872-80	27
1066	Should we routinely transfuse platelet for immune thrombocytopenia patients with platelet count less than 10 000/L who underwent laparoscopic splenectomy?. 2014 , 38, 2267-72	16
1065	Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. 2014 , 33, 1347-9	11
1064	[Autoimmune cytopenias: diagnosis before treatment. Reply by the authors]. 2014 , 80, e81	
1063	ITP and international guidelines: what do we know, what do we need?. 2014 , 43, e61-7	29
1062	Factors predictive of neonatal thrombocytopenia in pregnant women with immune thrombocytopenia. 2014 , 99, 570-6	12
1061	A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding. 2014 , 32, 801-13	5
1060	Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). 2014 , 176, 291-300	66
1059	Immune thrombocytopenia during childhood: new approaches to classification and management. 2014 , 165, 437-9	3
1058	Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. 2014 , 166, 592-600	69
1057	[Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France]. 2014 , 21, 85-93	3
1056	[Current treatment of primary immune thrombocytopenia]. 2014 , 142, 399-405	1
1055	Pierwotna maóprótkowoimmunologiczna u dzieci w wietle wspóczesnych definicji. 2014 , 45, 69-75	

1054	A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?. 2014 , 165, 756-67		27
1053	Acquired bleeding disorders. 2014 , 32, 691-713		7
1052	Relapse of immune thrombocytopenia associated with varicella 20 years after splenectomy. 2014 , 53, 2721-3		2
1051	Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. 2014 , 99, 1264-71		58
1050	Hematologic manifestations of Helicobacter pylori infection. 2014 , 20, 12818-38		37
1049	[Immune thrombocytopenia -- onkopedic guidelines update: recommendations of a joint working group of the DGHO, ÖHO, SGH + SSH and GPOH]. 2014 , 37 Suppl 2, 6-25		8
1048	Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies. 2014 , 69, 437-48		18
1047	Active exercise in critically ill adults affected by thrombocytopaenia. 2014 , 21, 41-45		1
1046	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014 , 123, 3887-94	2.2	78
1045	Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia. <i>Blood</i> , 2014 , 123, 422-7	2.2	21
1044	Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. <i>Blood</i> , 2014 , 123, 3906-8	2.2	52
1043	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. <i>Blood</i> , 2014 , 124, 2858-66	2.2	44
1042	Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. <i>Blood</i> , 2014 , 124, 3295-307	2.2	76
1041	Inhibition of Fc β -mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc β IIb on human macrophages. <i>Blood</i> , 2014 , 124, 3709-18	2.2	65
1040	Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. <i>Blood</i> , 2014 , 124, 3308-15	2.2	170
1039	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. <i>Blood</i> , 2014 , 124, 3228-36	2.2	104
1038	Health-related quality of life in children with newly diagnosed immune thrombocytopenia. 2014 , 99, 1525-31		28
1037	Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. 2014 , 112, 65-72		19

1036	Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy. 2014 , 124, 481-483		28
1035	Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review. 2015 , 45, 381-4		25
1034	Erstdiagnose einer Autoimmunthrombozytopenie in der Schwangerschaft mit schwerem Verlauf. 2015 , 5, 70-73		
1033	Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). 2015 , 62, 208-213		51
1032	Romiplostim in the management of the thrombocytopenic surgical patient. 2015 , 55, 2505-10		20
1031	Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. 2015 , 100, 623-32		54
1030	A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , 2015 , 125, 1541-7	2.2	59
1029	ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization. <i>Blood</i> , 2015 , 125, 869-72	2.2	44
1028	Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. <i>Blood</i> , 2015 , 125, 1470-6	2.2	137
1027	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. <i>Blood</i> , 2015 , 126, 873-9	2.2	104
1026	An efficient REDCap based data collection platform for the Primary Immune Thrombocytopenia and its analysis over the conventional approaches. 2015 ,		0
1025	Immune Thrombocytopenic Purpura: Between Infections and Vaccinations. 2015 , 271-282		
1024	Outcomes of total hip arthroplasty in patients with primary immune thrombocytopenia. 2015 , 16, 278		6
1023	Management of Activity in Immune Thrombocytopenia, Fat or Fit?. 2015 , 62, 2069-70		
1022	How we use WinRho in patients with idiopathic thrombocytopenic purpura. 2015 , 55, 2547-50		1
1021	Intrinsically impaired platelet production in some patients with persistent or chronic immune thrombocytopenia. 2015 , 170, 408-15		11
1020	Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia. 2015 , 97, 186-93		7
1019	An adult blind man presenting severe impairment of the right finger, ecchymosis in the thorax region, and haemorrhagic blisters on the oral mucosa. 2015 , 29, 1235-6		0

1018	Response to 'experience with the dermatology inpatient hospital service for adults: Mayo Clinic, 2000-2010'. 2015 , 29, 1236-7		1
1017	Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. 2015 , 2015,		4
1016	Mycophenolate mofetil therapy for severe immune thrombocytopenia. 2015 , 171, 625-30		40
1015	Hemostatic Management of Severe Thrombocytopenia in a Patient Undergoing Pulmonic Valve Replacement. 2015 , 5, 3-5		1
1014	Head trauma and intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. 2015 , 31, 454-8		6
1013	7. Hämatologische Diagnostik.		
1012	[Acquired amegakaryocytic thrombocytopenia purpura: think of systemic lupus erythematosus]. 2015 , 20, 86		2
1011	Late results after splenectomy in adult idiopathic thrombocytopenic purpura. 2015 , 19, e2013.00272		18
1010	The Differential Diagnosis of Thrombocytopenia in Pregnancy. 2015 , 112, 795-802		25
1009	Roles of peripheral B1 cells in the individualized treatment of adult idiopathic thrombocytopenic purpura. 2015 , 14, 21-8		1
1008	Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. 2015 , 32, 323-8		4
1007	Assessment of Immature Platelet Fraction in the Diagnosis of Wiskott-Aldrich Syndrome. 2015 , 3, 49		12
1006	Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia. 2015 , 3, 70		13
1005	Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort. 2015 , 3, 79		40
1004	Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia. <i>PLoS ONE</i> , 2015 , 10, e0126601	3-7	9
1003	Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia. 2015 , 10, 2180-2186		1
1002	Refractory thrombocytopenia and neutropenia: a diagnostic challenge. 2015 , 7, e2015018		6
1001	Total Hip Arthroplasty for Rapidly Destructive Coxarthrosis in a Patient with Severe Platelet Deficiency due to Liver Cirrhosis and Immune Thrombocytopenic Purpura. 2015 , 2015, 469879		

999	The management of immune thrombocytopenic purpura. 2015 , 27, 109-12		1
998	A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). <i>Blood</i> , 2015 , 126, 500-3	2.2	47
997	Management of immune-mediated cytopenias in pregnancy. 2015 , 14, 806-11		11
996	Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. 2015 , 26, 93-6		11
995	Decreased serum heat shock protein 60 levels in newly diagnosed immune thrombocytopenia patients. 2015 , 26, 220-3		3
994	Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus. 2015 , 24, 746-50		23
993	CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. <i>Blood</i> , 2015 , 126, 247-56	2.2	43
992	Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?. 2014 , 5, 674		82
991	Rituximab leads to long remissions in patients with chronic immune thrombocytopenia. 2015 , 30, 111-4		3
990	Romiplostim as a treatment for immune thrombocytopenia: a review. <i>Journal of Blood Medicine</i> , 2015 , 6, 37-44	2.3	18
989	Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. 2015 , 90, 301-5		19
988	Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports. 2015 , 3, 337-41		4
987	Maximal Dexamethasone Inhibition of Luminal Epithelial Proliferation Involves Progesterone Receptor (PR)- and Non-PR-Mediated Mechanisms in Neonatal Mouse Uterus. 2015 , 92, 122		5
986	Lack of impact of cytotoxic T-lymphocyte antigen 4 gene exon 1 polymorphism on susceptibility to or clinical course of egyptian childhood immune thrombocytopenic purpura. 2015 , 21, 378-82		4
985	Platelet analysis in laboratory hematology. 2015 , 38,		1
984	Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain. 2015 , 144, 389-396		
983	Drug-Immune Thrombocytopenia with Thrombosis versus Heparin-Induced Thrombocytopenia: A Critical Clinical Controversy. 2015 , 5, 152-9		0

982	Novel parameters in blood cell counters. 2015 , 35, 209-24	16
981	Rituximab for adult primary immune thrombocytopenia. 2015 , 2, e52-3	2
980	Acute and Chronic Infections: Their Role in Immune Thrombocytopenia. 2015 , 859-876	
979	The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments. 2015 , 94, 541-5	13
978	Treatment of pediatric primary immune thrombocytopenia with thrombopoietin receptor agonists. 2015 , 52, 25-30	6
977	Intravenous immunoglobulin in critically ill adults: When and what is the evidence?. 2015 , 30, 652.e9-16	18
976	Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. 2015 , 94, 739-46	12
975	Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patients. 2015 , 101, 268-72	3
974	Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review. 2015 , 2, 35-42	8
973	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. 2015 , 101, 255-63	40
972	Newly diagnosed immune thrombocytopenic purpura in childhood: successful implementation of a limited intervention strategy in the setting of pediatric emergency care. 2015 , 166, 480-2	2
971	Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. 2015 , 385, 1653-61	121
970	Dapsone for immune thrombocytopenic purpura in children and adults. 2015 , 26, 164-7	24
969	Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. 2015 , 26, 672-9	4
968	Störungen der Blutgerinnung in der Schwangerschaft. 2015 , 48, 94-100	
967	Disappointing response to dapsone as second line therapy for primary ITP: a case series. 2015 , 94, 1053-4	6
966	Chronic and Persistent Immune Thrombocytopenia: Guideline for Follow-up Care?. 2015 , 31, 398	
965	Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. 2015 , 386, 1649-58	129

964	Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia. 2015 , 166, 63-4	4
963	Quercetin intraperitoneal administration ameliorates lipopolysaccharide-induced systemic inflammation in mice. 2015 , 137, 89-97	35
962	Integrated analysis of long-term safety in patients with chronic immune thrombocytopenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. 2015 , 102, 259-70	66
961	Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. 2015 , 134, 215-28	15
960	STAT1 single nucleotide polymorphisms and susceptibility to immune thrombocytopenia. 2015 , 48, 305-12	7
959	Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia. 2015 , 212, 1255-66	56
958	Disorders of Thrombosis and Hemostasis in Pregnancy. 2015 ,	
957	Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period. 2015 , 45, 718-24	12
956	B-cell depletion in immune thrombocytopenia. 2015 , 385, 1599-601	
955	Blood disorders typically associated with renal transplantation. 2015 , 3, 18	29
954	Recommandations d'utilisation des agonistes du r�cepteur de la thrombopo�tine dans le purpura thrombophique immunologique de lâ�nfant et de lâ�adolescent. 2015 , 3, 4-12	2
953	Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients. 2015 , 61, 269-80	19
952	Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. 2015 , 102, 7-11	34
951	Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. 2015 , 90, E40-3	90
950	Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults. 2015 , 15, 2	11
949	Interleukin 35 may contribute to the loss of immunological self-tolerance in patients with primary immune thrombocytopenia. 2015 , 169, 278-85	13
948	The significance and management of thrombocytopenia in antiphospholipid syndrome. 2015 , 17, 14	34
947	Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?. 2015 , 133, 78-82	3

946	Fatigue in immune thrombocytopenia. 2015 , 170, 141-9		46
945	Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. 2015 , 170, 218-22		18
944	Cytokine profile of patients with chronic immune thrombocytopenia affects platelet count recovery after <i>Helicobacter pylori</i> eradication. 2015 , 168, 421-8		17
943	<i>Helicobacter pylori</i> Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography. 2015 , 20, 239-51		38
942	Eltrombopag for treatment of thrombocytopenia-associated disorders. 2015 , 16, 2243-56		15
941	Lower Extremity Wounds in Patients With Idiopathic Thrombocytopenic Purpura and Systemic Lupus Erythematosus. 2015 , 14, 224-30		4
940	Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. 2015 , 6, 7737		171
939	Current Management of Primary Immune Thrombocytopenia. 2015 , 32, 875-87		76
938	Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider. <i>European Journal of Haematology</i> , 2015 , 94, 169-76	3.8	7
937	Human immunoglobulin (KIOVIG [®] /GAMMAGARD LIQUID [®]) for immunodeficiency and autoimmune diseases: an observational cohort study. 2015 , 7, 753-63		4
936	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. 2015 , 2, e315-25		112
935	Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. 2015 , 102, 654-61		11
934	Thrombocytopenia in Pregnancy: Gestational Thrombocytopenia and Immune Thrombocytopenic Purpura. 2015 , 261-277		1
933	Peri-delivery Analgesia and Anesthesia in Women with Hemostatic or Thrombotic Disorders. 2015 , 365-390		
932	Decreased expression of IL-33 in immune thrombocytopenia. 2015 , 28, 420-4		7
931	Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?. 2015 , 5, 287-296		
930	Self-assessment. 2015 , 25, 592-596		
929	Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. 2015 , 95, 157-67		40

928	Clinical features of gestational thrombocytopenia difficult to differentiate from immune thrombocytopenia diagnosed during pregnancy. 2015 , 41, 44-9	15
927	Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. 2015 , 14, 168-73	13
926	Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia. 2015 , 26, 645-50	38
925	[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain]. 2015 , 144, 389-96	4
924	Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura?. 2015 , 26, 573-6	17
923	Immune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkey. 2015 , 94, 459-66	5
922	Antiphospholipid Antibody Syndrome. 2015 ,	1
921	Immune Thrombocytopenia. 2015 , 51-55	0
920	Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. 2015 , 52, 16-24	26
919	Laboratory clues to immunodeficiency; missed chances for early diagnosis?. 2015 , 68, 1-5	11
918	Hematologic Problems in the Critically Ill. 2015 ,	
917	An improved flow cytometric immunobead array to detect autoantibodies in plasma from patients with immune thrombocytopenic purpura. 2015 , 438, 396-400	9
916	[Immune thrombocytopenia and pregnancy: State of knowledge and unanswered questions]. 2015 , 36, 167-72	3
915	Immune thrombocytopenia: recent progress in pathophysiology and treatment. 2015 , 21, 397-404	14
914	Perioperative Hemostasis. 2015 ,	2
913	Immune thrombocytopaenia in pregnancy: Key principles for the midwife. 2016 , 24, 768-772	
912	Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9 1
911	Platelet destruction in immune thrombocytopenia. Understanding the mechanisms. <i>Hamostaseologie</i> , 2016 , 36, 187-94	1.9 9

910	Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. 2016 , 7, 7489-96		10
909	Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab. 2016 , 51, 297-299		1
908	<i>Helicobacter pylori</i> and Hematologic Diseases. 2016 ,		
907	Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines. 2016 , 8, e2016010		14
906	Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia. 2016 , 5, 1-7		1
905	Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis. 2016 , 2016, 5403612		4
904	Perinatal Management for a Pregnant Woman with an MYH9 Disorder. 2016 , 2016, 6730174		1
903	A study of platelet disorders in pregnancy. 2016 , 2377-2379		
902	Allogeneic hematopoietic stem cell transplantation: transfusion issues. 2016 , 29		6
901	Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?. 2016 , 51, 66		
900	The Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and Pathogenesis. 2016 , 4, 102		14
899	Disorders of Platelets. 2016 , 239-278		0
898	Cytokine gene polymorphism [tumor necrosis factor-alpha (-308), IL-10 (-1082), IL-6 (-174), IL-17F, 1RaVNTR] in pediatric patients with primary immune thrombocytopenia and response to different treatment modalities. <i>Blood Coagulation and Fibrinolysis</i> , 2016 , 27, 313-23	1	7
897	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. 2016 , 31, 149-62		297
896	Acute Disseminated Encephalomyelitis. 2016 , 31, 163-202		
895	Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study. <i>Blood Coagulation and Fibrinolysis</i> , 2016 , 27, 47-52	1	8
894	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. 2016 , 63, 1407-13		52
893	How we manage immune thrombocytopenia in the elderly. 2016 , 173, 844-56		21

892	Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. <i>European Journal of Haematology</i> , 2016 , 96, 269-75	3.8	20
891	Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. 2016 , 91, E267-72		50
890	Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review. <i>Blood Coagulation and Fibrinolysis</i> , 2016 , 27, 825-827	1	3
889	Delayed-onset thrombocytopenia in a pediatric burn patient. 2016 , 91, 958-60		1
888	The impact of cell labelling technique on the retention of indium-labelled platelet imaging for idiopathic thrombocytopenic purpura. 2016 , 37, 215-6		1
887	Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. 2016 , 91, E293-5		25
886	Comparison between IV immune globulin (IVIg) and anti-D globulin for treatment of immune thrombocytopenia: a randomized open-label study. 2016 , 30, 385-9		10
885	Practice Bulletin No. 166: Thrombocytopenia in Pregnancy. 2016 , 128, e43-53		35
884	Quantitative Platelet Disorders. 2016 , 134-159		
883	Bacterial Pneumonia-induced Persistent Remission of Severe Immune Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. 2016 , 55, 179-83		0
882	Tazobactam and piperacillin-induced thrombocytopenia: A case report. 2016 , 11, 1223-1226		9
881	Role of Laparoscopic Splenectomy in Elderly Immune Thrombocytopenia. 2016 , 11, 361-368		2
880	Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim. 2016 , 12, 96		6
879	Low-level light treatment ameliorates immune thrombocytopenia. 2016 , 6, 38238		10
878	Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. 2016 , 6, 39003		32
877	Congenital and acquired bleeding disorders in pregnancy. 2016 , 2016, 232-235		6
876	Warm antibody autoimmune hemolytic anemia. 2016 , 2016, 690-697		57
875	Treatment in idiopathic thrombocytopenic purpura in the elderly: about a retrospective study. 2016 , 14, 151-7		1

874	Long-term complications of splenectomy in adult immune thrombocytopenia. <i>Medicine (United States)</i> , 2016 , 95, e5098	1.8	41
873	Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia. 2016 , 14, 301		8
872	Anemia and other hematological problems in the elderly. 2016 , 523-536		
871	When and how to treat childhood immune thrombocytopenia. 2016 , 41, 18-25		
870	Reemergence of Splenectomy for ITP Second-line Treatment?. 2016 , 264, 772-777		20
869	The expression profile of toll-like receptor signaling molecules in CD19(+) B cells from patients with primary immune thrombocytopenia. 2016 , 176, 28-35		4
868	A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients. 2016 , 27, 555-62		14
867	Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients. 2016 , 53 Suppl 1, S43-7		10
866	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. 2016 , 388, 45-54		96
865	Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. 2016 , 104, 85-91		15
864	Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective. 2016 , 55, 1045-58		9
863	Refractory autoimmune disease: an overview of when first-line therapy is not enough. 2016 , 53 Suppl 1, S35-8		1
862	Identifying the characteristics, natural behavioral pattern, and response to therapy in ITP in a multi-center population in Sri Lanka. 2016 , 21, 375-8		1
861	Treatment of patients with immune thrombocytopenia admitted to the emergency room. 2016 , 104, 216-22		6
860	10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders. 2016 , 8, 923-40		1
859	Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. 2016 , 95, 1089-98		19
858	Tuberculosis an Emerging Cause of Immune Thrombocytopenia in Children: Literature Review. 2016 , 10, 063-067		
857	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. 2016 , 95, 1077-87		34

856	Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies. 2016 , 103, 655-64		29
855	Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia. 2016 , 76, 869-78		18
854	High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. <i>Blood</i> , 2016 , 127, 296-302; quiz 370	2.2	117
853	Huckepack durch die Kinderonkologie. 2016 ,		
852	Impact of preoperative platelet count on perioperative outcome after laparoscopic splenectomy for idiopathic thrombocytopenic purpura. 2016 , 94, 399-403		3
851	Impact of Preoperative Platelet Count on Perioperative Outcome After Laparoscopic Splenectomy for Idiopathic Thrombocytopenic Purpura. 2016 , 94, 399-403		
850	How I treat refractory immune thrombocytopenia. <i>Blood</i> , 2016 , 128, 1547-54	2.2	85
849	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , 2016 , 128, 1625-30	2.2	50
848	Blind men and the refractory ITP elephant. <i>Blood</i> , 2016 , 128, 1537-8	2.2	1
847	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. 2016 , 5, 1631-1643		38
846	Cyclosporin A for persistent or chronic immune thrombocytopenia in children. 2016 , 95, 1881-6		13
845	Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report. 2016 , 20, 1148-1151		4
844	The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia. 2016 , 44, 924-930.e1		18
843	Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. 2016 , 111, 116-123		114
842	Reproductive Issues in Women with Bleeding and Thrombotic Disorders. 2016 , 649-659		
841	Rotavirus-associated immune thrombocytopenic purpura in children: A retrospective study. 2016 , 12, 2187-2190		2
840	High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. 2016 , 3, e489-e496		78
839	High-dose dexamethasone or oral prednisone for immune thrombocytopenia?. 2016 , 3, e453-e454		3

838	Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. <i>European Journal of Haematology</i> , 2016 , 97, 321-30	3.8	36
837	Is ITP a thrombophilic disorder?. 2016 , 91, 39-45		71
836	Cytokine-induced killer cell therapy-associated idiopathic thrombocytopenic purpura: rare but noteworthy. 2016 , 8, 1003-9		1
835	Management of Adult Chronic Immune Thrombocytopenia in Japan: Patient and Hematologist Perspectives from a Multi-center Cross-sectional Questionnaire Survey. 2016 , 55, 2379-85		5
834	Immune thrombocytopenia: a comprehensive review from pathophysiology to promising treatment modalities. 2016 , 4, 1217-1227		1
833	Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. 2016 , 101, 1039-45		35
832	Association of DNA Methyltransferase 3B Promotor Polymorphism With Childhood Chronic Immune Thrombocytopenia. 2016 , 47, 312-317		6
831	An update on indications for platelet transfusion. 2016 , 11, 170-176		
830	Successful obstetric and hematologic outcome of aplastic anemia in a pregnant Jehovah's Witness. 2016 , 29, 543-8		2
829	Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity. 2016 , 16, 55		10
828	Hypomegakaryocytic thrombocytopenia (HMT): an immune-mediated bone marrow failure characterized by an increased number of PNH-phenotype cells and high plasma thrombopoietin levels. 2016 , 175, 246-251		9
827	Thrombocytopenia. 2016 , 43, 543-557		20
826	Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia. <i>Blood</i> , 2016 , 128, 2183-2185	2.2	7
825	Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration. 2016 , 13, 50		15
824	Procoagulant profile in patients with immune thrombocytopenia. 2016 , 175, 925-934		25
823	Immune-Mediated Thrombocytopenia. 2016 , 209-220		
822	Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand. 2016 , 43, 375-379		11
821	Kind met blauwe plekken en petechiën. 2016 , 59, 514-514		

820	Laparoscopic splenectomy for second-line treatment of immune thrombocytopenia – analysis of 53 patients and current perspectives. 2016 , 48, 273-277		3
819	Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. <i>Medicine (United States)</i> , 2016 , 95, e5565	1.8	29
818	Advances in Diagnosis and Treatments for Immune Thrombocytopenia. 2016 , 9, 15-22		31
817	Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines. 2016 , 63, 1227-31		17
816	The "platelet boilermaker": A treatment protocol to rapidly increase platelets in patients with immune-mediated thrombocytopenia. 2016 , 91, E330-1		4
815	Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. 2016 , CD011980		8
814	Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim. 2016 , 2, 81-3		
813	'On-demand' romiplostim therapy in immune thrombocytopenia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 351-353	2.2	4
812	Increased RUNX1 expression in patients with immune thrombocytopenia. 2016 , 77, 687-691		6
811	Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?. 2016 , 53 Suppl 1, S64-6		2
810	Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study. 2016 , 135, 162-71		23
809	Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales. 2016 , 19, 614-22		9
808	Immune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto's Thyroiditis: Role of Levothyroxine in Improving the Clinical Outcome of ITP. 2016 , 4, 2324709616647085		7
807	Health-related quality of life in children with chronic immune thrombocytopenia in China. 2016 , 14, 45		10
806	Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlook. 2016 , 53 Suppl 1, S39-42		1
805	Common variable immunodeficiency, immune thrombocytopenia, rituximab and splenectomy: important considerations. 2016 , 128, 567-72		2
804	An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia. 2016 , 56, 1739-44		5
803	Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. 2016 , 91, 907-11		31

802	Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. 2016 , 172, 262-73		96
801	Flow cytometric measurement of platelet-associated immunoglobulin in children with newly diagnosed Immune Thrombocytopenia. <i>European Journal of Haematology</i> , 2016 , 96, 397-403	3.8	7
800	Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. <i>European Journal of Haematology</i> , 2016 , 97, 297-302	3.8	24
799	Correlation Between Abnormal Platelet Count and Respiratory Viral Infection in Patients From Cheonan, Korea. <i>Journal of Clinical Laboratory Analysis</i> , 2016 , 30, 185-9	3	13
798	Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis. 2016 , 22, 248-51		19
797	Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. <i>Blood Coagulation and Fibrinolysis</i> , 2016 , 27, 431-5	1	3
796	Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?. 2016 , 110, 5-11		7
795	B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy. 2016 , 79, 262-70		21
794	Kompendium Kinderh�matologie. 2016 ,		1
793	Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. 2016 , 21, 257-62		19
792	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. 2016 , 27, 472-8		11
791	Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia. 2016 , 64, 604-9		17
790	Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study. 2016 , 103, 180-8		14
789	Risk and mortality of gastrointestinal hemorrhage in patients with thrombocytopenia: Two nationwide retrospective cohort studies. 2016 , 27, 86-90		2
788	Stromal cell-derived factor-1 rs2297630 polymorphism associated with platelet production and treatment response in Chinese patients with chronic immune thrombocytopenia. 2016 , 27, 338-43		6
787	Is there still a place for "old therapies" in the management of immune thrombocytopenia?. 2016 , 37, 43-9		21
786	Thrombocytopenic syndromes in pregnancy. 2016 , 9, 15-20		9
785	Thrombocytopenia in pregnancy. 2016 , 36, 146-52		8

784	The effect of single course high dose dexamethasone on CD28/CTLA-4 balance in the treatment of patients with newly diagnosed primary immune thrombocytopenia. 2016 , 12, 97-103	3
783	Diagnosis and treatment of inherited thrombocytopenias. 2016 , 89, 141-53	34
782	A Study of Human Killer Cell Immunoglobulin-Like Receptor and Multidrug Resistance Gene Polymorphisms in Children With Immune Thrombocytopenia. 2016 , 22, 429-40	3
781	The antiphospholipid syndrome: from pathophysiology to treatment. 2017 , 17, 257-267	56
780	Factors associated with the effect of open splenectomy for immune thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2017 , 98, 44-51	3.8
779	Abnormal Distribution and Function of Monocyte Subsets in Patients With Primary Immune Thrombocytopenia. 2017 , 23, 786-792	5
778	Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. 2017 , 15, 785-791	14
777	Purpura thrombophique immunologique chez un patient de 55 ans. 2017 , 7, 42-44	
776	Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. 2017 , 188, 275-282	19
775	The role of splenectomy in autoimmune hematological disorders: Outdated or still worth considering?. 2017 , 31, 159-172	12
774	A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. 2017 , 137, 66-72	29
773	[Epidemiology and pharmacoepidemiology of immune thrombocytopenia]. 2017 , 38, 444-449	7
772	Romiplostim therapy as a second-line treatment before splenectomy for refractory immune thrombocytopenia in a cirrhotic patient with iatrogenic Cushing syndrome secondary to corticosteroids. 2017 , 5, 159-163	1
771	Thrombocytopenia. 2017 , 45, 221-224	1
770	State of the art - how I manage immune thrombocytopenia. 2017 , 177, 39-54	71
769	Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. 2017 , 92, 493-500	33
768	Update on Thrombocytopenia in Pregnancy and Neuraxial Anesthesia. 2017 , 7, 111-118	
767	Splenectomy for Haematological Disorders. 2017 , 137-154	

766	Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. 2017 , 33, 581-585		4
765	Study of CD4, CD8, and natural killer cells (CD16, CD56) in children with immune thrombocytopenic purpura. 2017 , 10, 8-14		9
764	Cost of Bleeding-related Episodes in Adult Patients With Primary Immune Thrombocytopenia: A Population-based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States. 2017 , 39, 603-609.e1		8
763	Emerging drugs for immune thrombocytopenia (ITP). 2017 , 22, 27-38		10
762	Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation. 2017 , 44, 23-28		4
761	Pathogenesis of immune thrombocytopenia. 2017 , 16, 620-632		148
760	Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. 2017 , 102, 1342-1351		32
759	Clinical updates in adult immune thrombocytopenia. <i>Blood</i> , 2017 , 129, 2829-2835	2.2	200
758	Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. 2017 , 22, 484-492		3
757	Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. 2017 , 155, 86-91		30
756	Immune Thrombocytopenia. 2017 , 6, 53-66		
755	Immune thrombocytopenia of childhood responsive to tonsillectomy in the setting of chronic tonsillitis: A case report and literature review. 2017 , 38, 639-641		1
754	Relapsed Hydroxychloroquine Induced Thrombocytopenia in Systemic Lupus Erythematosus Patient. 2017 , 13, 294-296		
753	Neonatal Outcomes of Pregnancy with Immune Thrombocytopenia. 2017 , 33, 211-215		3
752	A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. <i>Blood</i> , 2017 , 130, 1097-1103	2.2	54
751	The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity. 2017 , 10, 649-657		10
750	Immune thrombocytopenia secondary to tuberculosis: a case and review of literature. 2017 , 21, 466-470		11
749	Goals defining therapy for primary immune thrombocytopenia in adults. <i>Blood Coagulation and Fibrinolysis</i> , 2017 , 28, 348-350	1	2

748	Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile. 2017 , 199, 204-211	49
747	Hematological Disorders in Children. 2017 ,	2
746	Using a standardised protocol was effective in reducing hospitalisation and treatment use in children with newly diagnosed immune thrombocytopenia. 2017 , 106, 1617-1623	3
745	Immune Thrombocytopenia: Where Are We Now?. 2017 , 749-760	
744	Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics. 2017 , 46, e13-e18	3
743	Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. 2017 , 177, 612-619	18
742	Thrombocytopenia in Pregnancy. 2017 , 813-823	1
741	Haematology of pregnancy. 2017 , 45, 251-255	2
740	Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. 2017 , 177, 475-480	5
739	Guidelines for the use of platelet transfusions. 2017 , 176, 365-394	224
738	New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia. 2017 , 112, 64-69	12
737	Update on the use of immunoglobulin in human disease: A review of evidence. 2017 , 139, S1-S46	302
736	Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. 2017 , 66, 6-30	1488
735	[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]. 2017 , 38, 167-175	10
734	Thrombocytopenia and infections. 2017 , 10, 99-106	34
733	Gammaflex 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. 2017 , 9, 1071-1088	3
732	Acquired Bleeding Disorders. 2017 , 31, 1123-1145	12
731	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. 2017 , 26, 1648-1661	27

730	Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. 2017 , 112, 767-772		12
729	Prophylactic platelet transfusions prior to surgery for people with a low platelet count. 2017 , 2017,		7
728	Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura. 2017 , 96, 2045-2056		3
727	Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions. 2017 , 5, 1660-1663		4
726	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. <i>Blood</i> , 2017 , 130, 2527-2536	2.2	147
725	Thrombocytopenia in childhood: a practical guide for investigation. 2017 , 27, 517-522		2
724	Managing and Supporting Surgery in Patients with Bleeding Disorders. 2017 , 43, 653-671		3
723	Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review and meta-analysis of 28 studies. <i>Medicine (United States)</i> , 2017 , 96, e7534	1.8	6
722	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. 2017 , 4, e487-e496		24
721	Effectiveness of <i>Helicobacter pylori</i> eradication in pregnant women with idiopathic thrombocytopenic purpura. 2017 , 43, 1212-1216		6
720	Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. <i>European Journal of Haematology</i> , 2017 , 99, 344-349	3.8	13
719	Primary immune thrombocytopenia in adults: clinical practice versus management guidelines. 2017 , 93, 645-646		3
718	Patterns of Emergency Department Care for Newly Diagnosed Immune Thrombocytopenia in United States Children's Hospitals. 2017 , 190, 265-267		1
717	Efficacy of Dexamethasone for Acute Primary Immune Thrombocytopenia Compared to Prednisolone: A Systematic Review and Meta-analysis. 2017 , 1, e73-e81		2
716	Indications et résultats de la splénectomie dans les pathologies hématoLOGIQUES. 2017 , 154, 433-442		1
715	Indications and outcome of splenectomy in hematologic disease. 2017 , 154, 421-429		23
714	SIC-reg.org: Managementleitfaden und Registerstudie für schwere Immundefizienzen. 2017 , 165, 772-779		1
713	Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case. 2017 , 5, 1385-1388		4

712	Mild bleeding disorders: what every clinician should know. 2017 , 78, 684-710		0
711	[Novelties in the treatment of pediatric immune thrombocytopenia - 2017]. 2017 , 158, 1891-1896		
710	New mechanisms of the TCM spleen-based treatment of immune thrombocytopenia purpura from the perspective of blood neurotransmitters. 2017 , 4, 106-112		1
709	Patterns of care and burden of chronic idiopathic thrombocytopenic purpura in Brazil. 2017 , 20, 884-892		
708	Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. 2017 , 106, 508-516		29
707	Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?. 2017 , 17, 796-802		8
706	Antibodies against complement-regulatory proteins on platelets in immune thrombocytopenia. 2017 , 28, 409-413		3
705	Long-term results of splenectomy in adult chronic immune thrombocytopenia. <i>European Journal of Haematology</i> , 2017 , 98, 235-241	3.8	26
704	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. 2017 , 105, 44-51		6
703	Advances in the pathophysiology of primary immune thrombocytopenia. 2017 , 22, 41-53		33
702	An increased expression profile of Th9/IL-9 correlated with Th17/IL-17 in patients with immune thrombocytopenia. 2017 , 28, 287-294		12
701	Childhood-onset autoimmune cytopenia as the presenting feature of biallelic ACP5 mutations. 2017 , 64, 306-310		2
700	Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. 2017 , 37, e23-e25		7
699	Flow cytometric analysis of platelet cyclooxygenase-1 and -2 and surface glycoproteins in patients with immune thrombocytopenia and healthy individuals. 2017 , 28, 387-393		3
698	Relapsed hydroxychloroquine induced thrombocytopenia in a systemic lupus erythematosus patient. 2017 , 13, 294-296		1
697	Case Reports of Idiopathic Thrombocytopenia Unresponsive to First-Line Therapies Treated With Traditional Herbal Medicines Based on Syndrome Differentiation. 2017 , 13, 68-74		1
696	Thymic-derived tolerizing dendritic cells are upregulated in the spleen upon treatment with intravenous immunoglobulin in a murine model of immune thrombocytopenia. 2017 , 28, 521-524		10
695	A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. <i>European Journal of Haematology</i> , 2017 , 98, 112-120	3.8	28

694	A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias. 2017 , 64, 287-293		5
693	Diagnosis and management of immune thrombocytopenia in childhood. <i>Hamostaseologie</i> , 2017 , 37, 36-44	9	27
692	Danazol: A treatment option for idiopathic thrombocytopenic purpura in hemodialysis patients. 2017 , 50, 635-640		
691	Risk factors of thrombocytopenia in pregnancy. 2017 , 6, 700		2
690	6. Fetale Anämie und Alloimmun-Thrombozytopenie. 2017 ,		1
689	9. Blutungsneigung in der Schwangerschaft und bei der Entbindung. 2017 , 215-242		
688	Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia. 2017 , 50, e5637		6
687	Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies. 2017 , 37, 484-493		15
686	Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). 2017 , 6,		187
685	Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis. 2017 , 2017, 7878605		6
684	Inflammation-Related Gene Polymorphisms Associated With Primary Immune Thrombocytopenia. 2017 , 8, 744		16
683	The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach. 2017 , 5, 179		10
682	Successful Long-Term Use of Eltrombopag in a Patient with Refractory Severe Thrombocytopenia Associated with Chronic Lymphocytic Leukemia That Allowed Oral Anticoagulant Treatment for Severe Cardiomyopathy. 2017 , 2017, 9538920		0
681	Role of Eradication Therapy on Platelet Recovery in Chronic Immune Thrombocytopenic Purpura. 2017 , 2017, 9529752		6
680	Management of newly diagnosed immune thrombocytopenia: can we change outcomes?. <i>Blood Advances</i> , 2017 , 1, 2295-2301	7.8	27
679	Management of immune thrombocytopenia: Korean experts recommendation in 2017. 2017 , 52, 254-263		14
678	Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients. <i>PLoS ONE</i> , 2017 , 12, e0187296	3.7	9
677	Plasma microRNAs characterising patients with immune thrombocytopenic purpura. 2017 , 117, 1420-1431		23

676	Report on the management of thrombocytopenia in obstetric patients: A retrospective study. 2017 , 9, 204-207		
675	Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases. 2017 , 34, 72-80		3
674	Autoimmune Hepatitis Associated with Immune Thrombocytopenic Purpura. 2017 , 56, 143-147		5
673	The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. 2017 , 9, 7034		1
672	The Effective Treatment with Cyclosporine of a Ulcerative Colitis Patient with Concurrent Idiopathic Thrombocytopenic Purpura Who Subsequently Developed Spontaneous Pneumomediastinum. 2017 , 56, 1331-1337		3
671	Immune thrombocytopenia. 2017 , 23, 206-212		
670	Dapsone therapy for refractory immune thrombocytopenia patients: a case series. 2017 , 52, 95-99		6
669	Management of newly diagnosed immune thrombocytopenia: can we change outcomes?. 2017 , 2017, 400-405		12
668	Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. <i>Blood Advances</i> , 2017 , 1, 2414-2420	7.8	60
667	Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. 2018 , 23, e12475		147
666	Mechanisms of platelet clearance and translation to improve platelet storage. <i>Blood</i> , 2018 , 131, 1512-1521		97
665	Fifteen-minute consultation: the child with a non-blanching rash. 2018 , 103, 236-240		4
664	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. 2018 , 93, 751-759		20
663	A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. 2018 , 181, 183-195		37
662	A characteristic flow cytometric pattern with broad forward scatter and narrowed side scatter helps diagnose immune thrombocytopenia (ITP). 2018 , 108, 151-160		3
661	Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices. 2018 , 93, 816-823		17
660	Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira - 2018. 2018 , 40, 50-74		12
659	Chinese guidelines for treatment of adult primary immune thrombocytopenia. 2018 , 107, 615-623		34

658	Mise au point: le purpura thrombophtique immunologique de lâenfant. 2018 , 31, 79-85		
657	A Randomized Multicenter Trial Comparing Low-Dose Prednisolone Versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia. 2018 , 24, 867-873		4
656	Temporal trends of splenectomy in pediatric hospitalizations with immune thrombocytopenia. 2018 , 65, e27072		12
655	Autoimmune Cytopenias in Pregnancy. 40-56		
654	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. 2018 , 18, 287-299		11
653	Nationwide Trend Analysis of Pediatric Inpatients With Immune Thrombocytopenia in the United States. 2018 , 40, e140-e144		9
652	Diminished expression of α -GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. 2018 , 97, 641-654		6
651	Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. 2018 , 97, 655-662		13
650	Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP). <i>European Journal of Haematology</i> , 2018 , 100, 412-418 ^{3,8}		1
649	Platelet count response to Helicobacter pylori eradication for idiopathic thrombocytopenic purpura in northeastern Brazil. 2018 , 40, 12-17		4
648	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. <i>Blood</i> , 2018 , 131, 1219-1233	2.2	26
647	Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. 2018 , 8, 576		8
646	Splenectomy for immune thrombocytopenia: down but not out. <i>Blood</i> , 2018 , 131, 1172-1182	2.2	86
645	Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. 2018 , 118, 143-151		30
644	Distinct alterations of CD68CD163 M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment. 2018 , 16, 48		15
643	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. 2018 , 93, 921-930		131
642	Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. 2018 , 4, CD011980		9
641	IL-10 polymorphisms and T-cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population. 2018 , 126, 380-388		5

640	Advances in chemical pharmacotherapy for the treatment of pediatric immune thrombocytopenia. 2018 , 19, 667-676	2
639	Developing role of eltrombopag in the treatment of aplastic anemia. 2018 , 6, 231-235	
638	Hemostasia primaria. 2018 , 22, 1-12	
637	Antibody Therapy. 2018 ,	
636	Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. 2018 , 265, 2494-2505	45
635	Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. 2018 , 125, 604-612	34
634	Evaluation of platelet function in thrombocytopenia. 2018 , 29, 270-276	26
633	"On-demand" treatment with Thrombopoietin mimetics as "bridge to recovery" from chemotherapy in chronic immune thrombocytopenia patients with cancer. A single centre experience in nine patients. 2018 , 181, 400-403	
632	Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study. 2018 , 34, 209-216	9
631	Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. 2018 , 48, 180-185	15
630	A highly purified form of staphylococcal protein A alleviates murine immune thrombocytopenia (ITP). 2018 , 183, 501-503	3
629	Autoimmune Cytopenias and Associated Conditions in COVID: a Report From the USIDNET Registry. 2018 , 38, 28-34	50
628	Platelet immunobiology: platelets as prey and predator. 2018 , 13, 87-92	2
627	Fostamatinib for persistent/chronic adult immune thrombocytopenia. 2018 , 10, 9-25	37
626	The potential association of tumor necrosis factor- β (252 G/A) cytokine gene polymorphism with immune thrombocytopenic purpura among Egyptian children. 2018 , 23, 299-303	1
625	Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis. 2018 , 103, 163-171	14
624	Oral manifestations of thrombocytopaenia. 2018 , 30, 19-25	1
623	The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura. 2018 , 23, 169-174	0

622	Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. 2018 , 107, 69-74	8
621	Tolerability and safety of the intravenous immunoglobulin octagam 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials. 2018 , 23, 242-247	4
620	A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag. 2018 , 108, 109-111	13
619	Adult Primary Immune Thrombocytopenia: Spleen Histology Findings and Outcomes According to Rituximab Use Based on Analysis of 41 Cases. 2018 , 42, 401-412	6
618	Refractory severe immune thrombocytopenia in a twin pregnancy. 2018 , 11, 35-38	6
617	Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia. 2018 , 10, 5-7	7
616	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. 2018 , 65, e26736	27
615	Dexamethasone as endocrine disruptor; type I and type II (anti) oestrogenic actions on the ovary and uterus of adult Wistar rats (). 2018 , 22, 307-313	1
614	Acute myocardial infarction and renal dysfunction due to chronic extreme anemia (hemoglobin 2.5 g/dL) in immune thrombocytopenia. 2018 , 31, 508-510	1
613	Platelet count on preoperative day 1 predicts the long-term responses to laparoscopic splenectomy for Chinese patients with medically refractory idiopathic thrombocytopenic purpura. 2018 , 18, 108	3
612	Severe immune thrombocytopenia in a patient taking benznidazole for chronic Chagas disease. <i>BMJ Case Reports</i> , 2018 , 2018,	0.9 1
611	Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis. 2018 , 2018, 1316096	11
610	Life-threatening outcomes after dental implantation in patient with idiopathic thrombocytopenic purpura: a case report and review of literature. 2018 , 40, 39	1
609	Isolated thrombocytopenia in childhood: what if it is not immune thrombocytopenia?. 2018 , 59, 390-393	8
608	Flow cytometry and immune thrombocytopenic purpura. 2018 , 57, 800-803	2
607	Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis. 2018 , 9, 7112-7125	8
606	Health-related quality of life in adult primary immune thrombocytopenia. 2018 , 11, 975-985	11
605	Immune thrombocytopenia: improving quality of life and patient outcomes. 2018 , 9, 369-384	25

604	Refractory Severe Thrombocytopenia during Pregnancy: How to Manage. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2018 , 40, 803-807	1.1	2
603	Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, IHO, SGH, GPOH, and DGTI. 2018 , 41 Suppl 5, 1-30		39
602	Management of immune thrombocytopenia in elderly patients. 2018 , 58, 70-76		5
601	Acute Brucellosis Presenting with Bleeding Tendency due to Isolated Severe Thrombocytopenia. 2018 , 2018, 7867435		4
600	A Quality Improvement Bundle to Improve Informed Choice for Children With Typical, Newly Diagnosed Immune Thrombocytopenia. 2018 , 40, e537-e543		0
599	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. 2018 , 8, e024427		16
598	Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. 2018 , 183, 479-490		69
597	Current and evolving treatment strategies in adult immune thrombocytopenia. 2018 , 11, 241-246		7
596	Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO. 2018 , 170, 200-206		5
595	Eltrombopag for use in children with immune thrombocytopenia. <i>Blood Advances</i> , 2018 , 2, 454-461	7.8	43
594	Pathophysiology of immune thrombocytopenia. 2018 , 25, 373-381		37
593	Low platelet counts in pregnancy: an alarm signal for abruption!. 2018 , 7, 1191		2
592	Thrombocytopenia in Pregnancy: Mechanisms and Management. 2018 , 32, 225-229		19
591	Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc-γ receptors. <i>Blood Advances</i> , 2018 , 2, 941-953	7.8	34
590	Pediatric ITP: is it different from adult ITP?. 2018 , 2018, 405-411		20
589	How do we diagnose immune thrombocytopenia in 2018?. 2018 , 2018, 561-567		15
588	Miscellaneous Conditions. 2018 , 309-325		
587	Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation. 2018 , 97, 1701-1706		16

586	Cutaneous Hemorrhage Types as Supportive Factors for Predicting Chronic Immune Thrombocytopenia in Children. 2018 , 40, 337-340		4
585	Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖHO, SGH, GPOH und DGTI. 2018 , 41 Suppl 2, 5-36		9
584	Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. 2018 , 9, 263-285		23
583	Treatment with cyclosporin in auto-immune cytopenias in children: The experience from the French cohort OBS'CEREVANCE. 2018 , 93, E196		2
582	Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. <i>Blood</i> , 2018 , 132, 883-891	2.2	37
581	Background of Immune Thrombocytopenia. 2018 , 3-15		
580	Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study. 2018 , 2018, 4138434		4
579	[Platelets - what should a GP know about]. 2018 , 160, 52-58		
578	A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies. 2018 , 2018, 8207017		1
577	Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. 2018 , 2018, 9429265		11
576	Autoimmune cytopenias and thrombotic thrombocytopenic purpura. <i>Clinical Medicine</i> , 2018 , 18, 335-339	1.9	4
575	The Treatment of Immune Thrombocytopenia. 2018 , 45-80		
574	Presentation and Evaluation of Immune Thrombocytopenia. 2018 , 35-44		
573	Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia. 2018 , 93, 139-144		3
572	Emerging Concepts in Immune Thrombocytopenia. 2018 , 9, 880		93
571	Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage. 2017 , 8, 737		4
570	Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. <i>European Journal of Haematology</i> , 2018 , 101, 549-555	1.8	12
569	Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature. 2018 , 12, 147		9

568	Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. 2018 , 16, 1830-1842		35
567	Evaluation of glucocorticoid compared with immunoglobulin therapy of severe immune thrombocytopenia during pregnancy: Response rate and complication. 2018 , 80, e13000		3
566	[Controversies in the treatment of paediatric immune thrombocytopenia]. 2018 , 89, 189.e1-189.e8		3
565	Updates in Immune Thrombocytopenia: Terminology, Immunomodulation and Platelet Stimulation, and Clinical Guidelines and Management. 2018 , 205-212		
564	Immune Hematology. 2018 ,		1
563	Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2018 , 29, 374-380	1	8
562	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. 2018 , 57, 1432-1438		17
561	Controversies in the treatment of paediatric immune thrombocytopenia. 2018 , 89, 189.e1-189.e8		
560	The Levels of T Lymphocyte Subsets in Immune Thrombocytopenia Associated with Anti-GPIIb/IIIa- and/or Anti-GPIb-Mediated Responses Are Differentially Sensitive to Dexamethasone. 2018 , 140, 60-66		7
559	Comment to the article by Arai Y, Jo T, Matsui H, Kondo T and Takaori-Kondo A: "Comparison of up-front treatments for newly diagnosed immune thrombocytopenia - a systematic review and network meta-analysis". <i>Haematologica</i> 2018;103(1):163-171. Need to direct immune thrombocytopenia therapy towards shared goals. 2018 , 103, e268		1
558	Outcome of different treatment regimens used in newly diagnosed ITP pediatric patients. 2018 , 66, 39-42		
557	ITP in Childhood: Predictors of Disease Duration. 2018 , 223-239		
556	Neonatal Platelet Disorders. 2018 , 1139-1151.e3		
555	Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice. <i>PLoS ONE</i> , 2018 , 13, e0198184	3-7	16
554	Splenectomy for Conditions Other Than Trauma. 2019 , 1635-1653		4
553	Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort. 2019 , 33, 475-485		9
552	Transcription Factor IRF4 Dysfunction Affects the Immunosuppressive Function of Treg Cells in Patients with Primary Immune Thrombocytopenia. 2019 , 2019, 1050285		6
551	Vincristine-loaded platelets coated with anti-CD41 mAbs: a new macrophage targeting proposal for the treatment of immune thrombocytopenia. 2019 , 7, 4568-4577		7

550	Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group. 2019 , 2019, 462-476		1
549	Modifying risk factors of chronicity in children with immune thrombocytopenia: Still underway. 2019 , 60, 357-358		1
548	Treating murine inflammatory diseases with an anti-erythrocyte antibody. 2019 , 11,		8
547	Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report. 2019 , 5, 56		2
546	Efficacy of vitamin D plus calcium with/without alendronate on bone metabolism in immunologic thrombocytopenic purpura patients with steroid treatment: Nine-month results of a randomized, double-blinded, controlled trial. 2019 , 18, 1391-1398		0
545	Protocol for the study and treatment of primary immune thrombocytopenia: ITP-2018. 2019 , 91, 127.e1-127.e10		
544	A HaemSTAR-led, UK-wide "flash-mob" audit of intravenous immunoglobulin use in immune thrombocytopenia. <i>Clinical Medicine</i> , 2019 , 19, 82-83	1.9	2
543	Immune thrombocytopenia (ITP): Pathophysiology update and diagnostic dilemmas. 2019 , 48 Suppl 1, 17-28		14
542	A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia. 2019 , 94, 1374-1381		17
541	Higher CD56+ or CD2+ lymphocyte percentage predicts poor steroid response in patients with immune thrombocytopenia. 2019 , 183, 63-68		2
540	Routine clinical care for chronic immune thrombocytopenia purpura in Denmark, 2009-2015. 2019 , 24, 732-736		1
539	Hypovitaminosis D Influences the Clinical Presentation of Immune Thrombocytopenia in Children with Newly Diagnosed Disease. 2019 , 8,		1
538	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. 2019 , 94, 1314-1324		29
537	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. 2019 , 56, 262-278		14
536	Severe thrombocytopenia in pregnancy: a case series from west China. 2019 , 19, 495-503		5
535	Diagnostik und Therapie der Immunthrombozytopenie. 2019 , 22, 47-55		1
534	Immune Thrombocytopenia. 2019 , 381, 945-955		113
533	Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis. <i>Hamostaseologie</i> , 2019 , 39, 227-237	1.9	15

532	Diagnosing Immune Thrombocytopenia. <i>Hamostaseologie</i> , 2019 , 39, 250-258	1.9	3
531	Rituximab - A novel therapy for severe ITP in pregnancy: A case report. 2019 , 12, 196-198		3
530	Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim. 2019 , 14, 80-87		9
529	Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. 2019 , 94, 461-466		6
528	Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. 2019 , 24, 290-299		9
527	Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopenia (The Bridging ITP Trial): Methods and Rationale. 2019 , 119, 500-507		3
526	All- retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1 β loop. 2019 , 104, 1661-1675		12
525	Eltrombopag in long-term management of pediatric thrombocytopenia. 2019 , 7, 196-201		4
524	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. 2019 , 104, 1124-1135		27
523	Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. 2019 , 57, 273-283		11
522	Obstetric neuraxial anesthesia at low platelet counts in the context of immune thrombocytopenia: a systematic review and meta-analysis. 2019 , 66, 1396-1414		6
521	A Narrative Approach to Describe QoL in Children With Chronic ITP. 2019 , 7, 163		7
520	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. 2019 , 34, 171-354		45 ^o
519	[Protocol for the study and treatment of primary immune thrombocytopenia: PTI-2018]. 2019 , 91, 127.e1-127.e10		
518	FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency. 2019 , 186, e163-e165		3
517	Evaluation of IVIG response in relation to Th1/Th2 cytokines in pediatric immune thrombocytopenia. 2019 , 120, 234-241		6
516	Excessive expressions of T cell activation markers in pediatric immune thrombocytopenia. 2019 , 180, 1-9		3
515	World Workshop on Oral Medicine VII: Platelet count and platelet transfusion for invasive dental procedures in thrombocytopenic patients: A systematic review. 2019 , 25 Suppl 1, 174-181		11

514	The abnormal function of CD39 regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia. 2019 , 98, 1845-1854	7
513	-induced thrombocytopenia: a retrospective study of 16 patients. 2019 , 47, 3008-3013	4
512	The effects of dexamethasone on 17βHSD1 levels at the rat optic nerve. 2019 , 27, 357-365	
511	High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/IGHJ4 gene in primary immune thrombocytopenia. 2019 , 9, 8645	4
510	Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. 2019 , 7, 32	25
509	Familial Immune Thrombocytopenia Associated With a Novel Variant in. 2019 , 7, 139	10
508	Measurement of platelet count with different anticoagulants in thrombocytopenic patients and healthy subjects: accuracy and stability over time. 2019 , 104, e570-e572	1
507	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719841735	5-7 36
506	Elective Cesarean Delivery. 2019 , 120-127	
505	Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. 2019 , 23, 212-216	3
504	High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia. 2019 , 10, 451	3
503	Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs. 2019 , 36, 10-22	13
502	Aberrant expression of microRNA in CD4 cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia. 2019 , 177, 70-78	13
501	Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center. 2019 , 66, e27704	1
500	Serum cytokines and clinical features in patients with fever and thrombocytopenia syndrome. 2019 , 494, 22-30	4
499	Immune Thrombocytopenia (ITP). 2019 , 707-724	1
498	Cytokine Profile, Apoptosis, Glucocorticoid Receptor, and P-glycoprotein Expression Before and After Megadose Methylprednisolone Treatment in Children With Acute Immune Thrombocytopenia. 2019 , 41, 574-578	2
497	Thrombocytopenic emergencies. 2019 , 80, C18-C21	

496	Thrombocytopenia in Pregnancy. 2019 , 795-812		0
495	Disseminated tuberculosis with severe immune thrombocytopenia. 2019 , 27, 100812		3
494	Antigenic Mimicry in Paraneoplastic Immune Thrombocytopenia. 2019 , 10, 523		4
493	Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy. 2019 , 19, 59		20
492	Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. 2019 , 104, 1237-1243		15
491	Primary and Secondary Immune Cytopenias: Evaluation and Treatment Approach in Children. 2019 , 33, 489-506		9
490	Diagnosis and management of primary immune thrombocytopenia in adults. 2019 , 80, C54-C57		2
489	Routine funduscopy in immune thrombocytopenic purpura-is it really necessary?. 2019 , 178, 957-960		2
488	ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy. 2019 , 133, e181-e193		43
487	Proposal of treatment algorithm for immune thrombocytopenia in adult patients of a hematology service at a referral center in Northeastern Brazil. 2019 , 41, 253-261		1
486	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopenia Patients Treated with Thrombopoietin Receptor Agonists. 2019 , 119, 645-659		19
485	Avatrombopag for the treatment of immune thrombocytopenia. 2019 , 15, 327-339		8
484	The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. 2019 , 17, 787-794		26
483	Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis. 2019 , 89, e12758		8
482	Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry. <i>European Journal of Haematology</i> , 2019 , 102, 416-423	3.8	10
481	Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 295-299	1	1
480	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. <i>Blood Advances</i> , 2019 , 3, 3515-3521	7.8	10
479	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267

478	The child with immune thrombocytopenia: to treat or not to treat, is that still the question?. 2019 , 104, 2132-2134		1
477	Primary Immune Thrombocytopenia: A Translational Research Model for Autoimmune Diseases. 2019 , 8,		1
476	Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?. 2019 , 94, 2199-2208		4
475	Disrupted balance of CD4 T-cell subsets in bone marrow of patients with primary immune thrombocytopenia. 2019 , 15, 2798-2814		17
474	Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab. 2019 , 42, 185-188		0
473	Patient characteristics when starting treatment and patterns of treatment in adults with chronic immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 350-356	1	3
472	Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report. <i>Medicine (United States)</i> , 2019 , 98, e15882	1.8	2
471	Sport and Children with Immune Thrombocytopenia: Never Give Up. 2019 , 18, 317-318		6
470	Treatment of primary and secondary immune thrombocytopenia. 2019 , 31, 213-222		15
469	Platelet and peripheral white blood cell counts at diagnosis predict the response of adult immune thrombocytopenia to recombinant human interleukin-11: A retrospective, single-center, case-control study. <i>Medicine (United States)</i> , 2019 , 98, e15195	1.8	2
468	Blockade of T-cell immunoglobulin and mucin domain-containing molecule 3 aggravates T-helper cell 1 polarization in immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 133-139	1	
467	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. 2019 , 41, e257-e259		1
466	Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model. 2019 , 67, 287-293		4
465	Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia. 2019 , 66, 362-365		10
464	Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia. 2019 , 35, 507-512		2
463	A biomarker and therapeutical target in immune thrombocytopenia: TNF receptor-associated factor 6. 2019 , 13, 27-31		1
462	The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. 2019 , 185, 410-417		5
461	Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. 2019 , 184, 424-430		10

460	Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. 2019 , 94, 200-208	13
459	Post-marketing dosing changes in the label of biologicals. 2019 , 85, 715-721	3
458	Assessment of IL-17F rs763780 gene polymorphism in immune thrombocytopenia. 2019 , 75, 20-25	2
457	Safety and efficacy of intravenous immunoglobulin (Flebogamma 10% DIF) in patients with immune thrombocytopenic purpura. 2019 , 11, 81-89	1
456	Novel Murine Model of Immune Thrombocytopaenia through Immunized CD41 Knockout Mice. 2019 , 119, 377-383	7
455	High dose dexamethasone as an alternative rescue therapy for active bleeding in children with chronic ITP: clinical and immunological effects. 2019 , 30, 886-892	5
454	Immuno-hematological Disorders. 2019 , 845-856.e1	
453	Kidney Transplant Management. 2019 ,	
452	Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis. 2019 , 30, 946-956	7
451	Platelet transfusion practices in immune thrombocytopenia related hospitalizations. 2019 , 59, 169-176	12
450	Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials. 2019 , 204, 225-233.e8	8
449	Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study. 2019 , 42, 77-83	7
448	Acquired Neonatal Thrombocytopenia. 2019 , 589-594	
447	Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. 2019 , 94, 118-132	19
446	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. 2019 , 108-126	4
445	Immune Thrombocytopenia. 2019 , 127-144	0
444	Therapeutic ApheresisâApplications for Hemorrhagic and Thrombotic Disorders. 2019 , 573-593	
443	Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center. 2019 , 30, 413-417	7

442	Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. 2019 , 25, 567-576	5
441	Risk factors associated with neonatal thrombocytopenia in pregnant women with immune thrombocytopenic purpura. 2020 , 33, 1572-1578	5
440	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. 2020 , 30, 116-124	1
439	First line treatment of adult patients with primary immune thrombocytopenia: a real-world study. 2020 , 31, 55-61	5
438	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. 2020 , 26, 48-56	30
437	Widely distributed purple-colored bullae and nodules in the oral cavity. 2020 , 129, 551-555	
436	Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. 2020 , 23, 184-192	11
435	Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). 2020 , 125, 154853	4
434	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). 2020 , 55, 441-451	13
433	Fibrinogen levels are associated with bleeding in patients with primary immune thrombocytopenia. 2020 , 31, 763-770	3
432	Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy. 2020 , 42, 283-286	2
431	Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. 2020 , 188, 450-459	11
430	How I approach new onset thrombocytopenia. 2020 , 31, 285-290	6
429	Fetal Platelet Disorders. 2020 , 497-507.e3	
428	The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States. 2020 , 31, 307-314	7
427	Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia. 2020 , 31, 291-299	2
426	Managing ITP and thrombocytopenia in pregnancy. 2020 , 31, 300-306	16
425	[Primary immune thrombocytopenia: Experience of a specialised clinic]. 2020 , 93, 16-23	

424	5 Years' Experience of a Tertiary Center with Thrombocytopenic Pregnancies: Gestational Thrombocytopenia, Idiopathic Thrombocytopenic Purpura and Hypertensive Disorders of Pregnancy. 2020 , 80, 76-83		4
423	Immune Thrombocytopenia: A Complex Autoimmune Disease. 2020 , 911-921		1
422	Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. 2021 , 106, 196-207		19
421	Genetic variants in toll-like receptor 4 are associated with lack of steroid-responsiveness in pediatric ITP patients. 2020 , 95, 395-400		1
420	Impact of Platelet Counts, Surgical Methods, and Preoperative Platelet Transfusion on the Outcome of Splenectomy for Immune Thrombocytopenia. 2020 , 143, 465-471		1
419	Managing Preoperative Hemostasis in Patients with Inherited and Acquired Bleeding Disorders. 2020 , 46, 17-25		2
418	First Line Treatments for Newly Diagnosed Primary Immune Thrombocytopenia in Children: A Systematic Review and Network Meta-analysis. 2020 , 16, 61-70		2
417	Management of immune thrombocytopenia in women: current standards and special considerations. 2020 , 13, 175-185		9
416	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. 2020 , 46, 275-288		23
415	Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. <i>European Journal of Haematology</i> , 2020 , 104, 259-270	3.8	4
414	Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. 2020 , 41, 100647		13
413	Is Thrombocytopenia Progressing? Immune Thrombocytopenic Purpura as Warning Sign for Significant Blood Disease. 2020 , 59, 512-515		1
412	Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. 2020 , 111, 329-351		23
411	The effect of mycophenolate mofetil on platelet function. <i>Blood Coagulation and Fibrinolysis</i> , 2020 , 31, 132-139	1	0
410	Cancer risk in patients with primary immune thrombocytopenia - A Swedish nationwide register study. 2020 , 69, 101806		2
409	Crosstalk Between Platelets and Microbial Pathogens. 2020 , 11, 1962		25
408	Pathogenesis of immune thrombocytopenia in common variable immunodeficiency. 2020 , 19, 102616		4
407	Cerebral Venous Thrombosis in a Patient with Immune Thrombocytopenia, an Apparent Paradox. 2020 , 13, 588-594		5

406	Manejo de la trombocitopenia inmune primaria. Comparaci3n de dos cohortes hist3ricas. 2020 ,		
405	Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. 2020 , 52, 1311-1322		2
404	Use of bioinformatic analyses in identifying characteristic genes and mechanisms active in the progression of idiopathic thrombocytopenic purpura in individuals with different phenotypes. 2020 , 48, 300060520971437		1
403	Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes. 2020 , 2, 19-24		1
402	Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trial. 2020 , 34, 2384-2397		4
401	First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. 2020 , 18, 3053-3060		8
400	High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. 2020 , 95, 1542-1552		15
399	Treatment of immune thrombocytopenia (ITP) secondary to malignancy: a systematic review. 2020 , 1-7		1
398	Comparison of antiplatelet antibody profiles between hepatitis C virus-associated immune thrombocytopenia and primary immune thrombocytopenia. 2021 , 32, 1043-1050		3
397	Predicting bleeding risk in a Chinese immune thrombocytopenia (ITP) population: development and assessment of a new predictive nomogram. 2020 , 10, 15337		0
396	Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study. <i>Journal of Blood Medicine</i> , 2020 , 11, 251-258	2.3	1
395	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. <i>Blood Advances</i> , 2020 , 4, 5846-5857	7.8	2
394	A case report of haemolytic disease of the foetus and newborn caused by Alloantibody D and Jka in a Rhesus D negative Nigerian woman: Justification for the implementation of universal access to prophylaxis and evidenced-based best practices. 2020 , 28, 245-252		
393	Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. 2020 , 39, 3099-3104		2
392	Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 2136-2138	7.8	0
391	Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States. 2020 , 12, 435-445		5
390	Immune thrombocytopenic purpura caused by the over-the-counter weight supplement Root of Tejocote (species). 2020 , 8, 872-876		2
389	Neonatal Immune Incompatibilities between Newborn and Mother. 2020 , 9,		2

388	Letter responds to the comment in 'immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty'. 2020 , 134, 60-61		
387	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620720912992	5.7	8
386	Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics. 2020 , 105, 618-629		4
385	Immune thrombocytopenia in adults: A single-centre review of demographics, clinical features and treatment outcomes. <i>European Journal of Haematology</i> , 2020 , 105, 344-351	3.8	1
384	Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	
383	Perioperative Management of Orthopaedic Patients with Hematologic Disorders: A Critical Analysis Review. 2020 , 8, e0001		1
382	The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. 2020 , 25, 139-144		7
381	Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. 2020 , 9, 447-457		6
380	Immune Thrombocytopenia. 2020 , 382, 1077		0
379	Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes. 2020 , 111, 771-778		3
378	Lifting the fog over ITP. 2020 , 31, 283-284		
377	Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. 2020 , 189, 931-942		4
376	Pediatric Bleeding Disorders. 2020 ,		
375	Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). 2020 , 7, 66		23
374	The association and functional relevance of genetic variation in low-to-medium-affinity Fc-gamma receptors with clinical platelet transfusion refractoriness. 2020 , 18, 2047-2053		1
373	Primary immune thrombocytopenia: Experience of a specialised clinic. 2020 , 93, 16-23		
372	Clinical Features, Treatment Courses, and Distribution of Cytomegalovirus Genotypes among Thrombocytopenia Patients Aged Younger than 12 Months. 2021 , 38, 1403-1411		1
371	Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy. 2020 , 135, 723-727		2

370	Reevaluation of platelet function in chronic immune thrombocytopenia: impacts of platelet size, platelet-associated anti- $\beta\beta$ antibodies and thrombopoietin receptor agonists. 2020 , 189, 760-771	5
369	An infant with refractory cytomegalovirus-induced thrombocytopenia. 2020 , 8, 75-78	0
368	Novel scientific approaches and future research directions in understanding ITP. 2020 , 31, 315-321	6
367	Detection and dynamics of anti-platelet antibodies in thrombocytopenic dogs with and without idiopathic immune thrombocytopenia. 2020 , 34, 700-709	4
366	Anti-platelet antibody immunoassays in childhood immune thrombocytopenia: a systematic review. 2020 , 115, 323-333	6
365	Quantitative Comparative Proteomics Reveals Candidate Biomarkers for the Early Prediction of Gestational Diabetes Mellitus: A Preliminary Study. 2020 , 34, 517-525	12
364	Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications. 2020 , 18, 1210-1220	5
363	Fatigue, executive function and psychological effects in children with immune thrombocytopenia: a cross-sectional study. 2020 , 189, 534-542	2
362	Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia. 2020 , 189, 369-378	13
361	Immune Thrombocytopenia in Children: Consensus and Controversies. 2020 , 87, 150-157	5
360	A study of thrombocytopenia in pregnancy. 2020 , 9, 1115	
359	Haemostatic disorders in pregnancy. 2020 , 20, 150-157	1
358	Thrombocytopenia in Pregnancy: Approach to Diagnosis and Management. 2020 , 46, 256-263	2
357	PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia. 2020 , 13, 227-234	1
356	Report of a 'consensus' on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine. 2020 , 31, 461-473	1
355	Revisiting the management of chronic ITP; a randomized controlled clinical trial. 2021 , 32, 243-249	1
354	Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. 2021 , 32, 633-641	0
353	14-month old boy with abrupt-onset petechiae and bruising. 2021 , 106, 35-37	

352	[Challenges and potential solutions in first-line treatments for immune thrombocytopenia in adults]. 2021 , 42, 25-31		1
351	Relation between mutations in the 5' UTR of ANKRD26 gene and inherited thrombocytopenia with predisposition to myeloid malignancies. An Egyptian study. 2021 , 32, 642-650		
350	Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children. <i>Blood</i> , 2021 , 137, 138-141	2.2	0
349	Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. 2021 , 110, 643-651		4
348	Myeloid-derived suppressor cells anticipate sustained treatment response in newly-diagnosed and persistent primary immune thrombocytopenia. 2021 , 87, 102529		
347	Immune thrombocytopenia (ITP) World Impact Survey (iWISH): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. 2021 , 96, 188-198		22
346	ITP Is Neither Idiopathic nor Always Benign. 2021 , 60, 193-194		
345	[Management of multirefractory immune thrombocytopenia]. 2021 , 42, 46-49		
344	Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. 2021 , 64, 766-783		3
343	Therapeutic efficacy and clinical effectiveness of mycophenolate mofetil and dexamethasone for immune thrombocytopenia: A retrospective observational study. 2021 , 10, 28		
342	Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. 2021 , 26, 225-239		18
341	Steroid-Resistant immune thrombocytopenia: Challenges and solutions. 2021 , 2, 33		
340	Immune Thrombocytopenia and Microangiopathies in Pregnancy. 2021 , 569-585		
339	HOW Collaborative position paper on the management of thrombocytopenia in pregnancy. 2021 , 61, 195-204		1
338	Preliminary Investigation about the Expression of G Protein-Coupled Receptors in Platelets from Patients with Chronic Immune Thrombocytopenic Purpura. 2021 , 144, 551-559		1
337	Inherited Bleeding Disorders in Pregnancy. 2021 , 351-362		
336	Induced Immune Thrombocytopenic Purpura and perspective role of eradication therapy for treating Immune Thrombocytopenic Purpura. 2021 , 7, 284-303		1
335	Bleeding Associated with Thrombocytopenia. 2021 , 141-156		

334	Tumor Necrosis Factor- β Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia. 2021 , 121, 767-781			3
333	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. 2021 , 144, 418-426			5
332	Preexistent chronic disorders, often directly affecting pregnancy. 2021 , 99-174			
331	Mitigation of patients with hematological disorders during the COVID-19 pandemic through telemedicine: the physician's perspectives. 77-84			
330	Update on the Use of Intravenous Immunoglobulin in Pregnancy. <i>NeoReviews</i> , 2021 , 22, e7-e24	1.1		1
329	The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia. 2021 , 75, e14057			1
328	Distribution of Clinically Relevant Blood Group Antigens among Nigerians and the Management of Rhesus D Negative Pregnancies: Implications for Haemolytic Disease of the Foetus and Newborn and Haemolytic Transfusion Reactions.			3
327	The role and mechanism of miR-557 in inhibiting the differentiation and maturation of megakaryocytes in immune thrombocytopenia. 2021 , 18, 1953-1968			4
326	UK second-line paediatric primary ITP therapy analysis. 2021 , 106, 929-931			0
325	Impact of eradication therapy of <i>Helicobacter pylori</i> in children with chronic immune thrombocytopenic purpura. 2021 , 69,			
324	Acquired Thrombocytopenias. 2021 , 210-222			
323	Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society. 2021 , 1-14			0
322	Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. 2021 , 10,			14
321	Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia. 2021 , 10, 21			2
320	Effect of eradication on patients with ITP: a meta-analysis of studies conducted in the Middle East. 2021 , 56, 38-43			4
319	Evidence-based clinical practice guideline for the management of primary immune thrombocytopenia (ITP) in pediatric population. 2021 , 69,			
318	Update on diagnosis and treatment of immune thrombocytopenia. 2021 , 14, 553-568			5
317	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. 2021 , 96, 561-570			2

316	Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. 2021 , 8, e289-e298		10
315	Thrombosis in immune thrombocytopenia - current status and future perspectives. 2021 , 194, 822-834		6
314	Recommendations for the treatment of immune thrombocytopenia in adults: a comparison. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 234-236	1	
313	Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice. 2021 , 38, 2673-2688		1
312	Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19. 2021 , 13, e14505		0
311	Clinical efficacy of high-dose dexamethasone with sequential prednisone maintenance therapy for newly diagnosed adult immune thrombocytopenia in a real-world setting. 2021 , 49, 3000605211007322		2
310	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021 , 138, 571-583	2.2	4
309	Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. 2021 , 194, 191-194		1
308	Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy. 2021 ,		
307	Hematologic Findings in Pregnancy: A Guide for the Internist. 2021 , 13, e15149		1
306	Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review. 2021 , 43, 281-287		0
305	Laser-assisted tooth extraction in patients with impaired hemostasis.. 2021 , 11, 47-54		0
304	The presence of idiopathic thrombocytopenic purpura correlates with lower rate of acute ST-elevation myocardial infarction. 2021 , 17, 1327-1333		0
303	Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine. 2021 , 8, 31-36		0
302	Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia. <i>Journal of Blood Medicine</i> , 2021 , 12, 421-429	2.3	
301	Immune thrombocytopenia associated with Hashimoto thyroiditis in a pediatric patient: A case report. <i>Medicine (United States)</i> , 2021 , 100, e26140	1.8	1
300	Could Anti-Nuclear Antibody Positivity be a Factor for Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?. 2021 ,		2
299	SIRT1 single-nucleotide polymorphisms are associated with corticosteroid sensitivity in primary immune thrombocytopenia patients. 2021 , 100, 2453-2462		0

298	Fc β 11a and Fc β 11a genes polymorphism in Egyptian children with primary immune thrombocytopenia. 2021 ,		
297	The status of Helicobacter pylori infection related extraintestinal diseases in Myanmar.		0
296	Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul.. 2022 , 38, 327-332		0
295	Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. <i>Journal of Blood Medicine</i> , 2021 , 12, 653-664	2.3	5
294	Decreased levels of immune-regulatory cytokines in patients with immune thrombocytopenia and long-lasting overexpression of these cytokines in the splenectomized patients. 2021 , 110, 335-341		0
293	Differential effects of Huaier aqueous extract on human CD4T lymphocytes from patients with primary immune thrombocytopenia. 2021 , 101-102, 58-67		1
292	Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in mice. <i>Blood Advances</i> , 2021 , 5, 4877-4889	7.8	0
291	Management of primary immune thrombocytopenia. A comparison between two historical cohorts. 2021 , 95, 86-92		
290	Preliminary Study on Apoptotic Proteins in Platelet from Adult Patients with Chronic Immune Thrombocytopenic Purpura. 2021 , 1-7		
289	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopenia (ITP) in children: study protocol. 2021 , 11, e044885		
288	A retrospective analysis of 122 immune thrombocytopenia patients treated with dapson: Efficacy, safety and factors associated with treatment response. 2021 , 19, 2275-2286		2
287	Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 519-521	1	1
286	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. 2021 , 49, 100811		4
285	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. 2022 , 45, 13-24		2
284	Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. 2021 , 385, 885-895		13
283	ESPED survey on newly diagnosed immune thrombocytopenia in childhood: how much treatment do we give?. 2021 , 8, 11		
282	Platelet Transfusion: An Update on Indications and Guidelines. 2021 , 41, 621-634		0
281	A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. 2021 , 195, 781-789		3

280	Oral Healthcare and Idiopathic Thrombocytopenic Purpura: Early Recognition, Dental Management and Case Report. 2021 , 9,		0
279	Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline. 2021 , 5, e489-e502		1
278	All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. 2021 , 8, e688-e699		5
277	The presence of idiopathic thrombocytopenic purpura and incidence of acute non-ST elevation myocardial infarction. 2021 , 1		0
276	Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia. 2021 , 27, 1447-1456		
275	Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia. 2020 , 11, 615941		6
274	Prophylactic platelet transfusions prior to surgery for people with a low platelet count. 2018 , 9, CD012779		12
273	Acquired Hemostatic Disorders. 2015 , 89-108		0
272	Physiologie des mütterlichen Organismus und Erkrankungen in der Schwangerschaft. 2015 , 1-80		1
271	Differential Diagnosis: Hypoplastic Thrombocytopenia. 2017 , 107-114		1
270	Diagnosis in General. 2017 , 87-95		1
269	Differential Diagnosis: Secondary ITP. 2017 , 97-105		2
268	Antiphospholipid syndrome - an update. 2018 , 47, 451-464		40
267	Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 71-74	1	4
266	Efficacy and safety of a new intravenous immunoglobulin (Panzyga) in chronic immune thrombocytopenia. 2019 , 29, 48-54		4
265	Coronary artery stenting in a patient with chronic immune thrombocytopenic purpura: a clinical conundrum. <i>BMJ Case Reports</i> , 2012 , 2012,	0.9	1
264	Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide. <i>BMJ Case Reports</i> , 2017 , 2017,	0.9	1
263	Immune Thrombocytopenia. 2010 , 2010, 377-384		7

262	Thrombocytopenia in pregnancy: is this immune thrombocytopenia or not? 2012 , 2012, 198-202		18
261	Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. <i>Blood</i> , 2018 , 131, 787-796	2.2	39
260	Blood Cell Disorders and the Nervous System. 2020 , 26, 659-674		1
259	Steroid-Induced Diabetes Ketoacidosis in an Immune Thrombocytopenia Patient: A Case Report and Literature Review. 2020 , 21, e923372		2
258	Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. <i>PLoS ONE</i> , 2015 , 10, e0142217	3.7	16
257	Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia. 2017 , 6, 81-86		5
256	Efficacy and Safety of IQYMUNE [®] , a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia. 2018 , 7, 87-95		1
255	Hematologic Complication of Respiratory Virus Infection. 2013 , 20, 178		3
254	Diagnostic Approach of Childhood Immune Thrombocytopenia. 2018 , 25, 10-16		1
253	Evaluation of the diagnostic performance of platelet-derived indices for the differential diagnosis of thrombocytopenia in pediatrics. 2015 , 62, 547-552		2
252	The Case of Acute Steroid-Induced Myopathy in the Patient with Autoimmune Thrombocytopenia. 2020 , 10, 314-321		0
251	Immune thrombocytopenic purpura presenting as unprovoked gingival hemorrhage: a case report. 2014 , 8, 164-7		1
250	Helicobacter pylori and hematological disorders. 2019 , 65, 204-213		9
249	Use of romiplostim for newly diagnosed immune thrombocytopenia in children. 2020 , 19, 18-26		2
248	Idiopathic thrombocytopenia and Helicobacter pylori infection: platelet count increase and early eradication therapy. 2011 , 9, 340-2		4
247	Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. 2012 , 10, 194-9		25
246	Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review. 2018 , 16, 307-312		6
245	Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits. 2011 , 96, 96-101		60

244	Association of CD4(+)CD25(+)FoxP3(+) regulatory T cells with natural course of childhood chronic immune thrombocytopenic purpura. 2015 , 58, 178-82	6
243	Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia. 2020 , 22,	7
242	[Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016)]. 2016 , 37, 89-93	11
241	[Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation]. 2016 , 37, 1065-1069	1
240	[Comparative study between two bleeding grading systems of primary immune thrombocytopenia]. 2017 , 38, 394-398	3
239	Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia. 2019 , 34, 383-389	1
238	Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia. 2020 , 35, 970-978	2
237	Bleeding disorders in orthopedic surgery. 2012 , 35, 1053-62	8
236	[Immune thrombocytopenia--pathophysiology and treatment]. 2010 , 130, 2120-3	6
235	Thrombocytosis following splenectomy and aortic valve replacement for idiopathic thrombocytopenic purpura with bicuspid aortic valve. 2015 , 59, 503-6	1
234	Association of IL-17A and IL-17F Gene Polymorphisms with Acute Immune Thrombocytopenia in Egyptian Children. 2018 , 08, 49-60	1
233	Laparoscopic splenectomy for primary immune thrombocytopenia: Current status and challenges. 2016 , 8, 610-5	9
232	A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience. 2019 , 36, 230-237	6
231	Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap. 2015 , 5, 45-8	7
230	Seasonal Association of Immune Thrombocytopenia in Adults. 2015 , 32, 347-51	3
229	[Haemostatic disorders in children]. <i>Hamostaseologie</i> , 2016 , 36, 109-25	1,9 8
228	Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding. 2012 , 17, 274-80	3
227	Successful Treatment of Idiopathic Thrombocytopenic Purpura After Liver Transplant: A Case Report. 2020 , 18, 649-652	0

226	Helicobacter pylori Infection and Hematologic Diseases. 2013 , 13, 214		1
225	A HaemSTAR-led, UK-wide "flash-mob" audit of intravenous immunoglobulin use in immune thrombocytopenia. <i>Clinical Medicine</i> , 2019 , 19, s82-s83	1.9	1
224	Intracranial hemorrhages in children with immune thrombocytopenia. 2021 , 20, 92-101		
223	The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. 2021 , 2021, 9992086		3
222	Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. <i>Blood Advances</i> , 2021 , 5, 4969-4979	7.8	2
221	Quantitative LC-MS/MS uncovers the regulatory role of autophagy in immune thrombocytopenia. 2021 , 21, 548		2
220	New developments in the diagnosis of primary immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2021 ,	1	1
219	Thrombopoietin receptor agonists for the treatment of severe persistent and chronic immune thrombocytopenia in children: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology. 2021 , 20, 12-25		1
218	Clinical observation of chronic myeloid leukemia with variant translocation and supplementary rearrangement t(1;8)(q23;q24.3). 2021 , 66, 424-432		
217	Prognostic evaluation of immune thrombocytopenia outcomes in Egyptian children: a retrospective single-center experience. 2021 , 20, 26-30		0
216	Efficacy of splenectomy in primary immune thrombocytopenia. 2021 , 66, 362-373		
215	Favorable prognosis of vaccine-associated immune thrombocytopenia in children is correlated with young age at vaccination: Retrospective survey of a nationwide disease registry. 2021 , 1		
214	Innovative therapies for ITP. 2010 , 21, 262-270		
213	Perinatale und pädiatrische Transfusionsmedizin. 2010 , 419-448		
212	Haematological problems. 2010 , 239-257		
211	Immunological thrombo-cytopenia in children. 2011 , 131, 13		
210	Blood Platelets and von Willebrand Disease. 2011 , 801-822		
209	Coagulopathy and Pregnancy. 2011 , 199-216		

- 208 Thrombocytopenia in Pregnancy: Gestational Thrombocytopenia and Idiopathic Thrombocytopenic Purpura. **2012**, 157-170
- 207 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 206 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 205 Thrombocytopenia. 102-107
- 204 Formulary Adjunct. **2012**, 989-1011
- 203 Hämorrhagische Diathesen und Hyperkoagulabilität. **2012**, 1127-1148
- 202 Task Force Report on Non-criteria Manifestations: Thrombocytopenia. **2012**, 195-206
- 201 Non-Neoplastic Disorders of Platelets. 31-44
- 200 Perioperative Management of the Patient with Immune Thrombocytopenic Purpura De Novo and the Thrombocytopenia of Antiphospholipid Antibody Syndrome. **2013**, 129-135
- 199 Rh (D) Immunglobulin. 217-225
- 198 Blutungs- und Gerinnungsstörungen. **2013**, 273-285
- 197 Comment je traite un syndrome d'Evans ou une cytophnie rfractaire au cours du lupus rythmateux ?. **2013**, 283-287
- 196 Immunoematologic disorders. **2013**, 749-759
- 195 Steroids. **2013**, 46-60
- 194 Les thrombophies immunologiques : physiopathologie et traitements. **2013**, 197, 407-417
- 193 Surgical approach. **2013**, 110-127
- 192 Successful Treatment of Two Patients with Immune Thrombocytopenic Purpura Using Herbal Decoction. **2013**, 34, 59-65
- 191 IDIOPATHIC THROMBOCYTOPENIC PURPURA IN PREGNANCY & NEONATAL EFFECTS â€”A CASE REPORT. **2013**, 2, 6100-6103

- 190 B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis. **2014**, 193-217 1
- 189 Diagnosing Thrombocytopenia in the Clinic. **2014**, 99-113
- 188 Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. **2014**, 112,
- 187 The Critically Ill Patient with Abnormal Platelet Count. **2015**, 59-79
- 186 THROMBOCYTOPENIA DURING PREGNANCY. **2014**, 4, 12956-12960
- 185 Differential Diagnosis. **2015**, 169-184
- 184 Non-Thrombotic Hematologic Manifestations in APS. **2015**, 113-126
- 183 Thrombotic Microangiopathies in Pregnancy. **2015**, 295-313 2
- 182 Immunthrombozytopenie (ITP) im Kindes- und Jugendalter (S2k). **2015**, K4a.1-K4a.8
- 181 Gerinnungsstörungen in der Geburtshilfe. **2015**, 1-38
- 180 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 179 Skin disease. **2015**, 262-271
- 178 Primary Immune Thrombocytopenia. 773-782
- 177 Immune Thrombocytopenia. 995-997
- 176 Acquired Thrombocytopenia. **2016**, 327-349
- 175 Bleeding Associated with Thrombocytopenia. **2016**, 103-117
- 174 Ernährung/Beruf und Dienst. **2016**, 151-160
- 173 Physiologie des mütterlichen Organismus und Erkrankungen in der Schwangerschaft. **2016**, 395-448

172 Hematological Problems in Pediatric Surgery. **2016**, 1-23

171 A Case of Megaloblastic Anemia with Thrombocytopenia. **2016**, 06, 534-538

1

170 Immunthrombozytopenie. **2016**, 133-142

169 Gerinnungsstörungen in der Geburtshilfe. **2016**, 971-996

168 Anomalies de la muqueuse buccale rvlant un purpura thrombophique immunologique. **2016**, 22, 151-157

o

167 Gebelike Trombositopeni. **2016**, 25, 420-432

166 Alemtuzumab in the treatment of multiple sclerosis: a haematologist perspective. **2016**, 17, 391-396

165 Management and Treatment of Primary Immune Thrombocytopenia in Children. **2017**, 217-229

164 ITP in Adults. **2017**, 75-84

163 Splenectomy. **2017**, 159-164

162 Therapy in Pregnancy. **2017**, 199-202

161 Clinical Manifestations of ITP in Children. **2017**, 205-215

160 Thrombophilia and Thrombocytopenia in the Pregnant Woman. **2017**, 55-76

159 Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice. **2017**, 10, 93-100

158 Immune and Inherited Thrombocytopenia in Children. **2017**, 173-187

157 Rituximab. **2017**, 165-169

156 Steroids. **2017**, 145-151

155 Thrombopoietin Receptor Agonists. **2017**, 171-181

- 154 Epidemiology. **2017**, 41-49 0
- 153 Hämorrhagische Diathesen. **2017**, 1033-1072
- 152 Low-level light treatment ameliorates immune thrombocytopenia. **2017**,
- 151 Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy. **2017**, 10, 435-442
- 150 High-Risk Pregnancy: Management Options. **2018**, 1
- 149 Hämorrhagische Diathesen und Hyperkoagulabilität. **2018**, 1-22
- 148 Thrombocytopenia in Pregnancy. **2017**, 5, 2
- 147 Literaturverzeichnis. **2018**, 503-517
- 146 Hämorrhagische Diathesen und Hyperkoagulabilität. **2018**, 1235-1256
- 145 Das thrombozytäre System. **2018**, 113-132
- 144 Diagnosis and treatment of immune thrombocytopenia. **2018**, 64, 526-529 1
- 143 GPIIB ALLELIC POLYMORPHISM AS A FACTOR ASSOCIATED WITH THE PROBABILITY OF IMMUNE THROMBOCYTOPENIA AND THE SEVERITY OF HEMORRHAGIC SYNDROME. **2018**, 13, 93-99
- 142 Post Kidney Transplant: Hematological Complications. **2019**, 151-164
- 141 The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents. **2018**, 1, 1-9
- 140 Management of adult immune thrombocytopenia: Recommendations by an expert Saudi panel. **2019**, 10, 77
- 139 Renal transplant in a patient with idiopathic thrombocytopenic purpura refractory to steroid and intravenous immunoglobulin. **2019**, 13, 228 0
- 138 Plasma-Derived Immunoglobulins. **2019**, 327-368
- 137 Successful Use of Eltrombopag in a Pediatric Patient With Human Immunodeficiency Virus (HIV)-Associated Thrombocytopenia. **2019**, 24, 242-246

136	Helicobacter pylori Eradication in Adult Patients with Acute Idiopathic Thrombocytopenic Purpura (ITP). 2019 , 27, 1-7		
135	A reservoir of rituximab-resistant splenic memory B cells contributes to relapses after B-cell depletion therapy.		1
134	Clinical effect and safety evaluation of different dosage of Rituximab combined with Cyclophosphamide in treatment of refractory immune Thrombocytopenia. 2020 , 36, 69-72		1
133	INTERIM RESULTS OF EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS IN THE RUSSIAN FEDERATION: INTERMEDIATE RESULTS. 2019 , 64, 436-446		2
132	Efficacy and safety of romiplostim in adult Iraqi patients with refractory immune thrombocytopenia. 2020 , 9, 92		
131	Vitamin D Insufficiency is Not Associated With Pediatric and Adolescent Immune Thrombocytopenia: A Study in Conjunction With its Receptor Genetic Polymorphisms. 2021 , 43, e1-e6		0
130	Laboratory Tests Used in the Diagnosis of Immune Thrombocytopenia and General Treatment Approaches. 2020 , 3, 22-36		
129	Prevalence and aetiology of moderate and severe thrombocytopenia in a tertiary and quaternary centre in KwaZulu-Natal. 2020 , 9, 799		1
128	Immune thrombocytopenia. 2021 , 1-13		1
127	Severe Immune Thrombocytopenia in Pregnancy: Intravenous Immunoglobulin Can Improve Platelet Count Significantly. 2020 , 36, 368-371		
126	New Developments in the Pathophysiology and Management of Primary Immune Thrombocytopenia. <i>Hamostaseologie</i> , 2021 , 41, 275-282	1.9	1
125	Role of platelet endothelial aggregation receptor 1 polymorphisms in idiopathic thrombocytopenic purpura: Is there an association?. 2021 , 10, 227		
124	Effect of gestational thrombocytopenia on negative fetal and maternal outcomes in low-risk pregnancies.		
123	Helicobacter pylori Infection: When Should It Be Treated?. 2020 , 81-102		0
122	Thrombocytopenia and disorders of platelet function. 2020 , 5520-5532		
121	Hematological Problems in Pediatric Surgery. 2020 , 387-409		
120	A Preteen Female with Fatigue and Incidental Finding of Thrombocytopenia. 2020 , 151-160		
119	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. 2020 , B-1-B30-3		

- 118 SDF-1 Facilitates Mesenchymal Stem Cells to Induce Regulatory B Cell Differentiation from Patients with Immune Thrombocytopenia. **2021**, 2021, 3254488
- 117 II. Pathophysiology and Treatment of Primary Immune Thrombocytopenia. **2020**, 109, 1347-1354
- 116 Hematology. 16-33
- 115 Treatment lines of childhood chronic ITP: A retrospective single-center analysis. **2020**, 19, 26-30
- 114 Reduced IL-35 in patients with immune thrombocytopenia. *Blood Coagulation and Fibrinolysis*, **2020**, 31, 543-550 1 1
- 113 Gene mutations in members of the PI3K/Akt signalling pathway are related to immune thrombocytopenia pathogenesis.
- 112 Öcukluk BİTİM. Trombositopenik Purpura (İTP) Hastaların Yaş Gruplarına Göre Değerlendirilmesi.
- 111 Fetal and Neonatal Alloimmune Thrombocytopenia. **2020**, 105-111
- 110 Disorders of Hemostasis. **2021**, 1-21
- 109 Perinatal outcome of pregnancies complicated by immune thrombocytopenia. **2012**, 14, 430-5 4
- 108 Therapeutic Options for Immune Thrombocytopenia (ITP) During Pregnancy. **2013**, 8, 182-8 4
- 107 Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. **2014**, 12, 605-7 5
- 106 Sunitinib Induced Immune Thrombocytopenia. **2015**, 14, 1295-7 3
- 105 Childhood immune thrombocytopenia: Clinical presentation and management. **2012**, 12, 27-39 2
- 104 Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. **2012**, 12, 60-4 3
- 103 Prednison provokes serum and vasoactive substances in a mice model of immune thrombocytopenia. **2016**, 19, 1010-1015 1
- 102 Efficacy and safety of ClairYg, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia. **2017**, 7, 1-9 0
- 101 Thrombocytopenia in Pregnancy. **2016**, 11, 55-60 8

100	Clinical Practice Updates in the Management Of Immune Thrombocytopenia. 2017 , 42, 756-763	14
99	The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature. 2018 , 7, 4-12	5
98	Effect Of Leaf Extract On Platelet Count In Chronic Immune Thrombocytopenic Purpura: A Case Series. 2019 , 18, 30-35	1
97	[A multicenter clinical trial of caffeic acid tablet in treatment of 103 primary immune thrombocytopenia patients]. 2015 , 36, 103-6	4
96	[Study on the relationship of platelet specific-autoantibodies with therapeutic outcomes by dexamethasone in immune thrombocytopenia purpura]. 2015 , 36, 202-5	1
95	[Efficacy and safety of recombinant human thrombopoietin in adult patients with primary immune thrombocytopenia during the perioperative period]. 2019 , 40, 191-194	
94	[Successful management of severe bleeding in a child of immune thrombocytopenia by preoperation splenic artery embolization plus laparoscopic splenectomy: a case report and literature review]. 2015 , 36, 66-7	
93	[A prospective study of the efficacy and safety of maintenance therapy with recombinant human thrombopoietin in patients with primary immune thrombocytopenia: a multicenter study]. 2017 , 38, 379-383	0
92	[How I treat corticosteroid-resistant or relapsed adult patients with primary immune thrombocytopenia]. 2017 , 38, 375-378	
91	[Interpretation of the updated international consensus report on the investigation and management of adult primary immune thrombocytopenia (version 2019)]. 2020 , 41, 89-92	
90	[American Society of Hematology 2019 guidelines and updated international consensus report for adult primary immune thrombocytopenia]. 2020 , 41, 441-445	0
89	Identification of Candidate Biomarkers for Idiopathic Thrombocytopenic Purpura by Bioinformatics Analysis of Microarray Data. 2020 , 19, 275-289	
88	[Pediatric expert consensus on the application of intravenous immunoglobulin in children with hematological/neoplastic diseases]. 2021 , 23, 319-327	
87	Evaluating association between idiopathic thrombocytopenic purpura and hypertension. 2021 , 11, 405-409	
86	Challenges Facing during Pregnancy and Measures to Overcome.	
85	Cellular Nanosponges for Biological Neutralization. 2021 , e2107719	5
84	Atorvastatin restores imbalance of cluster of differentiation 4 (CD4) T cells in immune thrombocytopenia in vivo and in vitro. 2021 ,	0
83	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. <i>Blood Advances</i> , 2021 ,	7.8 2

82	The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia. 2022 , 54, 132-137		
81	Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index.		
80	Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives.. 2022 , 14, 25-34		0
79	General Anesthesia for Cesarean Section in a Pregnant Woman with Immune Thrombocytopenic Purpura (ITP): A Case Report and Review of the Literature. 2022 , 12, 49-54		
78	Single dose versus low dose rituximab in corticosteroid-resistant or relapsed ITP: a multicenter, randomized, controlled study.. 2022 ,		0
77	Risk factors for severe neonatal thrombocytopenia in cases of maternal immune thrombocytopenia.. 2022 ,		0
76	Recent advances in the mechanisms and treatment of immune thrombocytopenia.. 2022 , 76, 103820		5
75	Immune Thrombocytopenia as the Initial Manifestation of Pediatric Systemic Lupus Erythematosus: Case Reports. 2022 , 10, 46-49		0
74	Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies.		
73	Real world, single centre experience of SARS-CoV-2 vaccination in Immune Thrombocytopenia.. 2022 ,		1
72	Real-world experience of anti-D immunoglobulin in immune thrombocytopenia.. 2022 , 1		0
71	A case involving eltrombopag administration for oral bleeding due to idiopathic thrombocytopenic purpura. 2021 , 67, 649-654		
70	Immune thrombocytopenia: what can the systems biology and systems physiology offer?. 2021 , 1, 1-9		1
69	Benefits of Helicobacter pylori Eradication on Extragastric Diseases. 2021 , 21, 275-286		
68	A Single-Arm, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia.. <i>Blood Advances</i> , 2022 ,	7.8	1
67	Data_Sheet_1.PDF. 2019 ,		
66	DataSheet_1.pdf. 2021 ,		
65	DataSheet_2.xlsx. 2021 ,		

64	Investigation of the correlation between immune thrombocytopenia and T cell activity-regulated gene polymorphism using functional study.. 2022 , 12, 6601		0
63	Pregnancy in a woman with chronic neutrophilic leukemia. 2013 , 121, 457-60		2
62	Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India.. 2022 ,		
61	Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.. <i>PLoS ONE</i> , 2022 , 17, e0267342	3.7	0
60	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221095226	5.7	1
59	Hämatologie und Onkologie. 2022 , 229-289		
58	Disorders of Hemostasis. 2022 , 1221-1241		
57	HDAC3 single-nucleotide polymorphism rs2530223 is associated with increased susceptibility and severity of primary immune thrombocytopenia.. <i>International Journal of Laboratory Hematology</i> , 2022 ,	2.5	1
56	Investigational drugs for immune thrombocytopenia.. <i>Expert Opinion on Investigational Drugs</i> , 2022 , 1-135.9		1
55	Thrombocytopenia: the good, the bad and the ugly.. <i>Clinical Medicine</i> , 2022 , 22, 214-217	1.9	0
54	Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system. <i>Journal of Clinical Pharmacy and Therapeutics</i> ,	2.2	
53	Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study. <i>Lupus Science and Medicine</i> , 2022 , 9, e000677	4.6	
52	Immune Thrombocytopenia: Characteristics of the Population and Treatment Methodsâ€”One-Center Experience. <i>Hamostaseologie</i> ,	1.9	
51	Postsplenectomy morbidity and mortality in patients with immune thrombocytopenic purpura: A national cohort study. <i>Journal of Surgical Oncology</i> ,	2.8	
50	İmmün trombositopenili erişkin hastalarda birinci basamak tedavide yüksek doz metilprednizolonun etkinliği <i>Cukurova Medical Journal</i> , 2022 , 47, 715-721	0.1	
49	Incidence of adult primary immune thrombocytopenia in England â€”an update. <i>European Journal of Haematology</i> ,	3.8	0
48	Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. <i>Blood Advances</i> ,	7.8	0
47	NMR-Based Metabolomics Identify Metabolic Change in Spleen of Idiopathic Thrombocytopenic Purpura Patients. <i>Metabolites</i> , 2022 , 12, 565	5.6	

46	Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia. <i>Journal of Blood Medicine</i> , Volume 13, 337-349 ^{2,3}		
45	Disorders of platelets and coagulation, thrombosis and blood transfusion. 2022 , 190-253		
44	Thrombopoietin Receptor Agonist in Pregnancy: a Case For Romiplostim in Refractory Immune Thrombocytopenic Purpura. <i>SN Comprehensive Clinical Medicine</i> , 2022 , 4,	2.7	o
43	Totla hip arthroplasty in patients with idiopathic thrombocytopenic purpura. <i>Travmatologiya i Ortopediya Rossii</i> ,	0.3	
42	Autoimmune storm following alemtuzumab. <i>BMJ Case Reports</i> , 2022 , 15, e248037	0.9	o
41	Pregnancy in Patients with Non-cirrhotic Portal Hypertension: A Literature Review. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022 , 44, 609-613	1.1	
40	Contribution of interleukin 27 serum level to pathogenesis and prognosis in children with immune thrombocytopenia. <i>Medicine (United States)</i> , 2022 , 101, e29504	1.8	
39	Evaluation of paediatric immune thrombocytopenia patients with clinical and laboratory findings: emphasizing the role of monocytosis. <i>Blood Coagulation and Fibrinolysis</i> , Publish Ahead of Print,	1	
38	Anemia and Other Hematological Problems. 2022 , 493-505		
37	Role of IL-10 and IL-22 cytokines in patients with primary immune thrombocytopenia and their clinical significance. <i>Journal of Clinical Laboratory Analysis</i> ,	3	
36	Immune-Mediated Neonatal Thrombocytopenia. <i>NeoReviews</i> , 2022 , 23, e462-e471	1.1	
35	Primary immune thrombocytopenia: a "diagnosis of exclusion". 2022 , 33, 289-294		o
34	Diagnostic Value of Peripheral Blood Lymphocytes for Primary Immune Thrombocytopenia. 2022 , 2022, 1-5		
33	Endothelial nitric oxide synthase Glu298asp gene polymorphism in the cases of idiopathic thrombocytopenic purpura. 2022 ,		
32	Thrombocytopenia in the first trimester predicts adverse pregnancy outcomes in obstetric antiphospholipid syndrome. 13,		o
31	Safety and efficacy of splenectomy for the treatment of chronic immune thrombocytopenia.		o
30	Bisphosphonate Use for Glucocorticoid-Induced Osteoporosis in Elderly Patients with Immune Thrombocytopenia Receiving Prolonged Steroid Therapy: A Single Institute Retrospective Study. 2022 , 14, 276-285		o
29	COVID-19 İhali Akut İmmün Trombositopenik Purpura: Sıradışı Pediatrik Bir Olgu. 1-4		o

28	Immune Thrombocytopenic Purpura and Paradoxical Thrombosis: A Systematic Review of Case Reports. 2022 ,	0
27	Lower-dose corticosteroid therapy in severe immune thrombocytopenia during pregnancy: The comparable efficacy and lower incidence of maternal complications. 13,	0
26	Possible Targets to Reduce Fatigue in Chronic Immune Thrombocytopenia Patients – An Explorative Study. 2022 , 06, e387-e395	0
25	Megakaryocyte- and Platelet-Derived Microparticles as Novel Diagnostic and Prognostic Biomarkers for Immune Thrombocytopenia. 2022 , 11, 6776	1
24	Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis. 2023 , 56, 101777	0
23	A Case of Immune Thrombocytopenic Purpura due to COVID-19 Vaccination that was Successfully Treated by Splenectomy. 2022 , 83, 931-936	0
22	Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. 2022 , 135, 2344-2350	0
21	Neonatal Implications of Maternal Thrombocytopenia during Pregnancy. 2022 , 23, e852-e855	0
20	Cost-effectiveness of a quality improvement initiative for the clinical management of children with newly diagnosed immune thrombocytopenia. 2022 ,	0
19	Predictors of Remission in Severe Childhood Immune Thrombocytopenia. 2023 , 13, 341	0
18	Comprehensive analysis of primary immune thrombocytopenia clinical trials in the ClinicalTrials.gov database.	0
17	Older Adults and Immune Thrombocytopenia: Considerations for the Clinician. Volume 18, 115-130	0
16	Biomarkers for predicting response to corticosteroid therapy for immune thrombocytopenic purpura.	0
15	Gene mutations in the PI3K/Akt signaling pathway were related to immune thrombocytopenia pathogenesis. 2023 , 102, e32947	0
14	A bibliometric analysis of primary immune thrombocytopenia from 2011 to 2021.	0
13	Case series of gestational thrombocytopenia. 2023 , 10, 96-98	0
12	Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study.	0
11	Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia. 2023 , 24, 4438	0

- 10 IVI g treatment increases thrombin activation of platelets and thrombin generation in paediatric patients with immune thrombocytopenia. ○
- 9 Identification factors to adjust early combination regimens in adult primary immune thrombocytopenia: An 8-year data analysis. 2, ○
- 8 Refractory splenectomized immune thrombocytopenic purpura: Does vincristine have a role after thrombopoietin receptor agonist failure?. **2022**, 47, 299 ○
- 7 Primary autoimmune thrombocytopenia in pregnancy: maternal and neonatal outcomes. 74-80 ○
- 6 The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia. ○
- 5 Effect of delivery mode on postnatal platelet count dynamics in neonates born to mothers with immune thrombocytopenia. ○
- 4 Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. **2023**, 24, 763-774 ○
- 3 Treatment of patients with COVID-19-associated immune thrombocytopenia in real clinical practice. **2023**, 115-123 ○
- 2 Australian and New Zealand consensus guideline for paediatric newly diagnosed immune thrombocytopenia endorsed by Australian New Zealand Children's Haematology and Oncology Group. ○
- 1 Use of dapsone in chronic/refractory immune thrombocytopenic patients: A single center experience. **2023**, 5, 70-76 ○